<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Fingolimod for relapsing‐remitting multiple sclerosis - La Mantia, L - 2016 | Cochrane Library</title> <meta content="Fingolimod for relapsing‐remitting multiple sclerosis - La Mantia, L - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009371.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Fingolimod for relapsing‐remitting multiple sclerosis - La Mantia, L - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009371.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009371.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Fingolimod for relapsing‐remitting multiple sclerosis" name="citation_title"/> <meta content="Loredana La Mantia" name="citation_author"/> <meta content="I.R.C.C.S. Santa Maria Nascente ‐ Fondazione Don Gnocchi" name="citation_author_institution"/> <meta content="lamantialore@gmail.com" name="citation_author_email"/> <meta content="Irene Tramacere" name="citation_author"/> <meta content="Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="Belal Firwana" name="citation_author"/> <meta content="University of Arkansas for Medical Sciences" name="citation_author_institution"/> <meta content="Ilaria Pacchetti" name="citation_author"/> <meta content="Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="Roberto Palumbo" name="citation_author"/> <meta content="Azienda Ospedaliera San Giovanni Addolorata" name="citation_author_institution"/> <meta content="Graziella Filippini" name="citation_author"/> <meta content="Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD009371.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009371.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009371.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009371.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Fingolimod Hydrochloride [adverse effects, *therapeutic use]; Immunosuppressive Agents [adverse effects, *therapeutic use]; Interferon‐beta [therapeutic use]; Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; Randomized Controlled Trials as Topic; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009371.pub2&amp;doi=10.1002/14651858.CD009371.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009371\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009371\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009371.pub2",title:"Fingolimod for relapsing\\u2010remitting multiple sclerosis",firstPublishedDate:"Apr 19, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009371.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009371.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009371.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009371.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009371.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009371.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009371.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009371.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009371.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009371.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4644 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009371.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0079"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-sec-0073"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/appendices#CD009371-sec-0084"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/table_n/CD009371StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/table_n/CD009371StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Fingolimod for relapsing‐remitting multiple sclerosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#CD009371-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Loredana La Mantia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#CD009371-cr-0003">Irene Tramacere</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#CD009371-cr-0004">Belal Firwana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#CD009371-cr-0005">Ilaria Pacchetti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#CD009371-cr-0006">Roberto Palumbo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information#CD009371-cr-0007">Graziella Filippini</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information/en#CD009371-sec-0088">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009371.pub2">https://doi.org/10.1002/14651858.CD009371.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009371-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009371-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009371-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009371-abs-0001" lang="en"> <section id="CD009371-sec-0001"> <h3 class="title" id="CD009371-sec-0001">Background</h3> <p>Fingolimod was approved in 2010 for the treatment of patients with the relapsing‐remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the frequency of exacerbations and to delay disability worsening. Issues on its safety and efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised. </p> </section> <section id="CD009371-sec-0002"> <h3 class="title" id="CD009371-sec-0002">Objectives</h3> <p>To assess the safety and benefit of fingolimod versus placebo, or other disease‐modifying drugs (DMDs), in reducing disease activity in people with relapsing‐remitting multiple sclerosis (RRMS). </p> </section> <section id="CD009371-sec-0003"> <h3 class="title" id="CD009371-sec-0003">Search methods</h3> <p>We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System (CNS) Group's Specialised Trials Register and US Food and Drug Administration reports (15 February 2016). </p> </section> <section id="CD009371-sec-0004"> <h3 class="title" id="CD009371-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) assessing the beneficial and harmful effects of fingolimod versus placebo or other approved DMDs in people with RRMS. </p> </section> <section id="CD009371-sec-0005"> <h3 class="title" id="CD009371-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as expected by Cochrane.</p> </section> <section id="CD009371-sec-0006"> <h3 class="title" id="CD009371-sec-0006">Main results</h3> <p>Six RCTs met our selection criteria. The overall population included 5152 participants; 1621 controls and 3531 treated with fingolimod at different doses; 2061 with 0.5 mg, 1376 with 1.25 mg, and 94 with 5.0 mg daily. Among the controls, 923 participants were treated with placebo and 698 with others DMDs. The treatment duration was six months in three, 12 months in one, and 24 months in two trials. One study was at high risk of bias for blinding, three studies were at high risk of bias for incomplete outcome reporting, and four studies were at high risk of bias for other reasons (co‐authors were affiliated with the pharmaceutical company). We retrieved 10 ongoing trials; four of them have been completed. </p> <p>Comparing fingolimod administered at the approved dose of 0.5 mg to placebo, we found that the drug at 24 months increased the probability of being relapse‐free (risk ratio (RR) 1.44, 95% confidence interval (CI) (1.28 to 1.63); moderate quality of evidence), but it might lead to little or no difference in preventing disability progression (RR 1.07, 95% CI 1.02 to 1.11; primary clinical endpoints; low quality evidence). Benefit was observed for other measures of inflammatory disease activity including clinical (annualised relapse rate): rate ratio 0.50, 95% CI 0.40 to 0.62; moderate quality evidence; and magnetic resonance imaging (MRI) activity (gadolinium‐enhancing lesions): RR of being free from (MRI) gadolinium‐enhancing lesions: 1.36, 95% CI 1.27 to 1.45; low quality evidence.The mean change of MRI T2‐weighted lesion load favoured fingolimod at 12 and 24 months. </p> <p>No significant increased risk of discontinuation due to adverse events was observed for fingolimod 0.5 mg compared to placebo at six and 24 months. The risk of fingolimod discontinuation was significantly higher compared to placebo for the dose 1.25 mg at 24 months (RR 1.93, 95% CI 1.48 to 2.52). </p> <p>No significant increased risk of discontinuation due to serious adverse events was observed for fingolimod 0.5 mg compared to placebo at six and 24 months. A significant increased risk of discontinuation due to serious adverse events was found for fingolimod 5.0 mg (RR 2.77, 95% CI 1.04 to 7.38) compared to placebo at six months. </p> <p>Comparing fingolimod 0.5 mg to intramuscular interferon beta‐1a, we found moderate quality evidence that the drug at one year slightly increased the number of participants free from relapse (RR 1.18, 95% CI 1.09 to 1.27) or from gadolinium‐enhancing lesions (RR 1.12, 95% CI 1.05 to 1.19), and decreased the relapse rate (rate ratio 0.48, 95% CI 0.34 to 0.70). We did not detect any advantage for preventing disability progression (RR 1.02, 95% CI 0.99 to 1.06; low quality evidence). We did not detect any significant difference for MRI T2‐weighted lesion load change. </p> <p>We found a greater likelihood of participants discontinuing fingolimod, as compared to other DMDs, due to adverse events in the short‐term (six months) (RR 3.21, 95% CI 1.16 to 8.86), but there was no significant difference versus interferon beta‐1a at 12 months (RR 1.51, 95% CI 0.81 to 2.80; moderate quality evidence). A higher incidence of adverse events was suggestive of the lower tolerability rate of fingolimod compared to interferon‐beta 1a. </p> <p>Quality of life was improved in participants after switching from a different DMD to fingolimod at six months, but this effect was not found compared to placebo at 24 months. </p> <p>All studies were sponsored by Novartis Pharma.</p> </section> <section id="CD009371-sec-0007"> <h3 class="title" id="CD009371-sec-0007">Authors' conclusions</h3> <p>Treatment with fingolimod compared to placebo in RRMS patients is effective in reducing inflammatory disease activity, but it may lead to little or no difference in preventing disability worsening. The risk of withdrawals due to adverse events requires careful monitoring of patients over time. The evidence on the risk/benefit profile of fingolimod compared with intramuscular interferon beta‐1a was uncertain, based on a low number of head‐to‐head RCTs with short follow‐up duration. The ongoing trial results will possibly satisfy these issues. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009371-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009371-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009371-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009371-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009371-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009371-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009371-abs-0004" lang="en"> <h3>Fingolimod for relapsing‐remitting multiple sclerosis</h3> <p><b>Background</b> </p> <p>Considering the autoimmune pathogenesis of multiple sclerosis (MS), most of the treatments have been based on the immunomodulatory and immunosuppressive properties of drugs such as interferons, glatiramer, azathioprine, cyclophosphamide and mitoxantrone. </p> <p>Fingolimod, was the first agent to gain approval as an oral treatment in 2010. It is efficiently absorbed, its absorption is unaffected by dietary intake and, as an oral therapy, it has aroused great interest in patients, having a more acceptable route of administration than injections. </p> <p><b>Aim of the review</b> </p> <p>To assess the safety and the benefits of fingolimod in reducing disease activity in people with relapsing‐remitting MS (RRMS). A number of safety concerns have already emerged, including serious infections and adverse cardiac effects. </p> <p><b>Study characteristics</b> </p> <p>Six studies, published between 2006 and 2014, were included in this review, comprising a total of 5152 participants suffering from RRMS. The treatment duration was six months in three studies, 12 months in one study, and 24 months in two studies. </p> <p><b>Key results and quality of evidence</b> </p> <p>The main conclusion of this review was that fingolimod, administered as monotherapy at the approved dose of 0.5 mg once‐daily increases the probability of being relapse‐free at 24 months compared to placebo. The benefit was confirmed with disease activity measures defined by magnetic resonance imaging (MRI) scans. However, there was no effect on preventing disability worsening; treatment was not associated with an increased risk of patient withdrawals due to adverse events. </p> <p>Comparing the same dose of fingolimod to intramuscular interferon beta‐1a, the drug at one year slightly increased the number of participants free from relapse or from inflammatory enhancing lesions and decreased the relapse rate. Again, we did not detect any advantage for preventing disability progression. We found a greater likelihood of discontinuation due to adverse events in the short‐term (six months) for fingolimod as compared to immunomodulating drugs, and no significant difference compared to interferon beta at 12 months. </p> <p>The duration of all studies was equal or inferior to 24 months, so that the efficacy (but mostly the safety) of fingolimod over 24 months remains uncertain. This is a key point for a lifetime disease with the probability of chronic treatments as in MS. </p> <p>The risk of adverse events requires careful monitoring of patients over time and suggests the need for studies with longer follow‐up, particularly considering the recent warning on the development of progressive multifocal leukoencephalopathy. </p> <p>The six studies included in this review were sponsored by Novartis Pharma, and most co‐authors of the published papers were affiliated to the pharmaceutical company; this is recognised as a potential source of bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009371-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-sec-0079">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-sec-0115">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009371-sec-0079"></div> <h3 class="title" id="CD009371-sec-0080">Implications for practice</h3> <section id="CD009371-sec-0080"> <p>The results of this review showed that fingolimod is a useful treatment of people with RRMS, because of its efficacy in the prevention of disease activity compared to placebo, although the benefit in terms of preventing disability worsening remains unclear. The direct comparison with other approved first‐line DMDs, in particular intramuscular interferon beta‐1a, indicates a higher benefit of fingolimod in terms of relapse prevention, but a significant risk of discontinuation in the first months of treatment. A higher incidence of adverse events was found, suggesting lower tolerability for fingolimod versus interferon beta‐1a, requiring careful monitoring over time. </p> <p>However, the data were inadequate, for the low number of head‐to‐head RCTs and types of comparisons, with short follow‐up duration. </p> </section> <h3 class="title" id="CD009371-sec-0081">Implications for research</h3> <section id="CD009371-sec-0081"> <p>There is a need to further explore the long‐term benefit and safety profile of fingolimod considering the risk of progressive multifocal leukoencephalopathy (<a href="./references#CD009371-bbs2-0061" title="Drug SafetyCommunication . Gilenya (Fingolimod): Drug Safety Communication ‐ FDA Warns About Cases of Rare Brain Infection. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm457183.htm(accessed December 2015). ">FDA 2015</a>), and basal cell carcinoma potentially associated with fingolimod therapy (<a href="./references#CD009371-bbs2-0057" title="European Medicines Agency. Gilenya : EPAR ‐ Summary for the public. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&amp;mid=WC0b01ac058004d5c1(accessed Decembre 2015). [ema.europa.eu/Find medicine/Humanmedicines/European Public Assessment Reports] ">EMA 2015</a>). Head‐to‐head trials comparing fingolimod with other DMDs, and the evaluation of drug effects using other outcome measures, including disease activity freedom (<a href="./references#CD009371-bbs2-0065" title="GiovannoniG , TurneraB , GnanapavanaS , OffiahcC , SchmiereraK , MartaM . Is it time to target no evident disease activity(NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders 215;4:329–33. ">Giovannoni 2015</a>), are useful to guide clinicians to personalise patient treatment. The ongoing, and as yet unpublished trials, will possibly satisfy these issues. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009371-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009371-sec-0022"></div> <div class="table" id="CD009371-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants or population:</b> people with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> outpatients in multiple sclerosis centres<br/> <b>Intervention:</b> fingolimod 0.5 mg versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes at 24 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (placebo)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fingolimod 0.5 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 100</b> <br/> (63 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b> <br/> (1.28 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 100</b> <br/> (83 to 91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> <br/> (1.02 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> l<b>ow<sup>a,b</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 100</b> <br/> (8 to 21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b> <br/> (0.89 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1556<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a,b,c</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Annualised relapse rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.50</b> <br/> (0.40 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from MRI gadolinium‐enhancing lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 100</b> <br/> (83 to 94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> <br/> (1.27 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1226<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> l<b>ow<sup>a,b</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*For dichotomous outcomes, the <b>corresponding risk with fingolimod 0.5 mg</b> (and its 95% CI) is based on the <b>assumed risk with the control group</b> (i.e. the mean proportion of events in the control group across the two studies) and the <b>relative effect</b> of fingolimod (and its 95% CI). For the annualised relapse rate, only the relative effect (i.e., the rate ratio) is given, because the assumed risk with the control group is not estimable.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Study limitations: significant differences in reasons for incomplete outcome data between treatment and control groups.<br/> <sup>b</sup> Imprecision: total number of events (i.e. the number of participants with disability worsening/gadolinium‐enhancing lesions) was less than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size criteria. Wide confidence intervals.<br/> <sup>c</sup> Inconsistency: unexplained heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009371-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fingolimod 0.5 mg versus interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Fingolimod 0.5 mg versus intramuscular interferon beta‐1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants or population:</b> people with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> outpatients in multiple sclerosis centres<br/> <b>Intervention:</b> fingolimod 0.5 mg versus intramuscular interferon beta‐1a </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes at 12 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (interferon beta‐1a)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fingolimod 0.5 mg </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 100</b> <br/> (76 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (1.09 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 100</b> <br/> (91 to 98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.99 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> l<b>ow<sup>a,b</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>4 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>6 per 100</b> <br/> (3 to 10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.51</b> <br/> (0.81 to 2.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>860<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Annualised relapse rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.48</b> <br/> (0.34 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from MRI gadolinium‐enhancing lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 100</b> <br/> (85 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (1.05 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>728<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*For dichotomous outcomes, the <b>corresponding risk with the intervention</b> (and its 95% CI) is based on the <b>assumed risk with the control</b> (i.e. the mean proportion of events in the control group across studies) and the <b>relative effect</b> of the intervention (and its 95% CI). For the annualised relapse rate, only the relative effect (i.e., the rate ratio) is given.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Imprecision: total number of events (i.e. the number of participants with disability worsening/gadolinium‐enhancing lesions) was less than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size criteria. </p> <p><sup>b</sup> Indirectness: surrogate outcome (progression confirmed at three months of follow‐up). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009371-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-sec-0095">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009371-sec-0023"></div> <section id="CD009371-sec-0024"> <h3 class="title" id="CD009371-sec-0024">Description of the condition</h3> <p>Multiple sclerosis (MS) is the most common nontraumatic cause of neurologic disability in young adults (<a href="./references#CD009371-bbs2-0048" title="CompstonA , ColesA . Multiple sclerosis. Lancet2002;359:1221‐31. ">Compston 2002</a>; <a href="./references#CD009371-bbs2-0090" title="NoseworthyJH , LucchinettiCF , RodriguezM , WeinshenkerBG . Multiple Sclerosis. New England Journal of Medicine2000;343:938‐52. ">Noseworthy 2000</a>). The overall incidence of MS is between 3.5 to 6.6 people per 100,000, while the prevalence rate is between 100 to 120 people per 100,000 (<a href="./references#CD009371-bbs2-0038" title="AlonsoA , HernanMA . Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology2008;71(2):129‐35. [PUBMED: 18606967] ">Alonso 2008</a>; <a href="./references#CD009371-bbs2-0101" title="RichardsRG , SampsonFC , BeardSM , TappendenP . A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technology Assessment2002;6(10):1‐73. [PUBMED: 12022938] ">Richards 2002</a>). A recent review showed an increase in the prevalence and incidence rate over time around the Mediterranean Basin, particularly in women ( <a href="./references#CD009371-bbs2-0056" title="ElhamiSR , MohammadK , SahraianMA , EftekharH . A 20‐year incidence trend (1989‐2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population‐based study. Neuroepidemiology2011;36(3):141‐7. ">Elhami 2011</a>). Western Europe and North America are high prevalence areas (<a href="./references#CD009371-bbs2-0074" title="Koch‐HenriksenN , SørensenPS . The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology2010;9:520–32. ">Koch‐Henriksen 2010</a>). The social cost associated with MS is high because of its long duration, the early loss of productivity, the need for assistance in activities of daily living and the use of highly expensive immunotherapy and multidisciplinary health care (<a href="./references#CD009371-bbs2-0075" title="KoutsourakiE , CostaV , BaloyannisS . Epidemiology of multiple sclerosis in Europe: a review. International Review of Psychiatry2010;22(1):2‐13. ">Koutsouraki 2010</a>). It is widely believed that MS is an immune‐mediated disease whose clinical manifestations and course, as well as response to therapy, appear to be heterogeneous, as may be the underlying pathogenic mechanisms (<a href="./references#CD009371-bbs2-0049" title="CompstonA , ColesA . Multiple sclerosis. Lancet2008;372:1502‐17. ">Compston 2008</a>). </p> <p>Different clinical subtypes of MS are distinguishable. Approximately 80% of patients have an initial disease course characterised by relapses and remissions (relapsing‐remitting MS (RRMS)). The remaining have primary or transitional progressive MS and experience progressive decline in neurological function from onset. In patients with RRMS, disability can result from one or more of the following: incomplete recovery from relapses, development of secondary progressive MS (SPMS), or cognitive impairment. However, as many as 17% of patients with benign MS never develop a clinically important physical disability (<a href="./references#CD009371-bbs2-0097" title="PittockSJ , McClellandRL , MayrWT , JorgensenNW , WeinshenkerBG , NoseworthyJ , et al. Clinical implications of benign multiple sclerosis: a 20‐year population‐based follow‐up study. Annals of Neurology2004;56:303‐6. ">Pittock 2004</a>). </p> <p>Considering the autoimmune pathogenesis of the disease, the mainstay of treatment has been based on immunomodulatory drugs, including interferon beta and glatiramer acetate, which are generally perceived as very safe drugs. However, they allow only a partial control of the disease. The available armamentarium has been expanding in recent years, with injectable and oral agents with more selective mechanisms of action and more efficacy (<a href="./references#CD009371-bbs2-0093" title="OhJ , O'ConnorPW . Safety, tolerability and efficacy of oral therapies for relapsing‐remitting multiple sclerosis. CNS Drugs2013;27:591‐609. ">Oh J 2013</a>). </p> </section> <section id="CD009371-sec-0025"> <h3 class="title" id="CD009371-sec-0025">Description of the intervention</h3> <p>Fingolimod is a sphingosine‐1‐phosphate (S1P)–receptor modulator, 2‐amino‐2‐(2‐[4‐octylphenyl]ethyl)‐1, 3‐propanediol (<a href="./references#CD009371-bbs2-0042" title="BrinkmannV , DavisMD , HeiseCE , AlbertR , CottensS , HofR . The immune modulator FTY720 targets sphingosine 1‐phosphate receptors. Journal of Biological Chemistry2002;277:21453‐7. ">Brinkmann 2002</a>). </p> <p>It is a prodrug, phosphorylated by sphingosine kinases to active phosphofingolimod. There are at least five S1P receptor subtypes, known as S1P subtypes 1‐5 (S1P1‐5), four of which bind fingolimod‐phosphate (<a href="./references#CD009371-bbs2-0044" title="ChunJ , HartungH . Mechanism of action of oral Fingolimod (FTY720) in multiple sclerosis. Clinical Neuropharmacology2010;33(2):91‐101. ">Chun 2010</a>). S1P1 is highly expressed on T and B lymphocytes. Fingolimod induces lymphocytes S1P1 down‐regulation, preventing the egress of cells from secondary lymphoid tissues (<a href="./references#CD009371-bbs2-0044" title="ChunJ , HartungH . Mechanism of action of oral Fingolimod (FTY720) in multiple sclerosis. Clinical Neuropharmacology2010;33(2):91‐101. ">Chun 2010</a>; <a href="./references#CD009371-bbs2-0096" title="PinschewerDD , OchsenbeinAF , OdermattB , BrinkmannV , HengartnerH , ZinkernagelRM . FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. Journal of Immunology2000;164:5761‐70. ">Pinschewer 2000</a>). Therefore, lymphocytes are retained away from the Central Nervous System (CNS) (<a href="./references#CD009371-bbs2-0082" title="MatloubianM , LoCG , CinamonG , LesneskiMJ , XuY , BrinkmannV , et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature2004;427:355‐60. ">Matloubian 2004</a>; <a href="./references#CD009371-bbs2-0096" title="PinschewerDD , OchsenbeinAF , OdermattB , BrinkmannV , HengartnerH , ZinkernagelRM . FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. Journal of Immunology2000;164:5761‐70. ">Pinschewer 2000</a>). After oral administration, fingolimod is efficiently absorbed and its absorption is unaffected by dietary intake. After administration of one dose, blood concentration of fingolimod increases steadily over the first 12 hours and remains elevated during the 24‐hour period until the next dose. It has a half‐life of six to nine days. Steady‐state blood concentrations are reached within one to two months following once‐daily administration and steady‐state levels are approximately 10‐fold greater than with the initial dose (<a href="./references#CD009371-bbs2-0050" title="DavidOJ , KovaricGM , SchmouderRL . Clinical pharmacokinetics of fingolimod. Clinical Pharmacokinetics2012;51(1):15‐28. ">David 2012</a>). </p> <p>Other effects of fingolimod are the transient activation of S1P receptors in atrial myocytes (associated with transient reduction of heart rate), the increase of lung hyperreactivity (associated with bronchospasm and airway constriction effects), mediated by S1P1 and S1P3 and a role in the regulation of endothelial permeability and vascular tone. Fingolimod has also been reported to be a competitive antagonist of cannabinoid receptors, and cannabinoid receptor activation has been shown to stimulate sphingomyelin catabolism (<a href="./references#CD009371-bbs2-0095" title="PaughS , CassidyM , HeH , MilstienS , Sim‐SelleyL , SpiegelS , et al. Sphingosine and its analog, the immunosuppressant 2‐Amino‐2‐(2‐[4‐octylphenyl]ethyl)‐1,3‐propanediol, interact with the CB1 cannabinoid receptor. Molecular Pharmacology2006;70:41–50. ">Paugh 2006</a>). </p> <p>Fingolimod can prevent renal graft rejections and suppress a variety of autoimmune disorders (<a href="./references#CD009371-bbs2-0079" title="LiuJ , ZhangC , TaoW , LiuM . Systematic review and meta‐analysis of the efficacy of sphingosine‐1‐phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. The International Journal of Neuroscience2013;123(3):163‐9. ">Liu 2013</a>). </p> <p>Fingolimod marketed as Gilenya ® (Novartis Pharma) is provided as 0.5 mg hard gelatin capsules for oral use, once‐daily. Each capsule contains 0.56 mg of fingolimod hydrochloride, equivalent to 0.5 mg of fingolimod. </p> </section> <section id="CD009371-sec-0026"> <h3 class="title" id="CD009371-sec-0026">How the intervention might work</h3> <p>Fingolimod has been shown to reduce disease activity and established neurologic deficits in animal models (<a href="./references#CD009371-bbs2-0042" title="BrinkmannV , DavisMD , HeiseCE , AlbertR , CottensS , HofR . The immune modulator FTY720 targets sphingosine 1‐phosphate receptors. Journal of Biological Chemistry2002;277:21453‐7. ">Brinkmann 2002</a>). Prophylactic administration of fingolimod to animals with experimental autoimmune encephalitis (EAE), a model of MS, completely prevents development of EAE, whereas therapeutic administration significantly reduces the clinical severity of EAE (<a href="./references#CD009371-bbs2-0044" title="ChunJ , HartungH . Mechanism of action of oral Fingolimod (FTY720) in multiple sclerosis. Clinical Neuropharmacology2010;33(2):91‐101. ">Chun 2010</a>). Phase II and phase III trials in RRMS patients showed significant reduction of the relapse rate and of the number of gadolinium‐enhancing, and new and/or enlarging T2 lesions on magnetic resonance imaging (MRI), as compared with placebo and with interferon beta‐1a (<a href="./references#CD009371-bbs2-0093" title="OhJ , O'ConnorPW . Safety, tolerability and efficacy of oral therapies for relapsing‐remitting multiple sclerosis. CNS Drugs2013;27:591‐609. ">Oh J 2013</a>). These effects have been related to sequestration of lymphocytes within lymph nodes, and a significant decrease in peripherally circulating lymphocytes, preventing autoaggressive lymphocytes from crossing the blood‐brain barrier. Some studies have shown that fingolimod may promote neuroprotective and reparative processes within the CNS through modulation of S1P receptors on glial and neural cells (<a href="./references#CD009371-bbs2-0084" title="MironVE , JungCG , KimHJ , KennedyTE , SolivenB , AntelGP . FTY720 modulates human oligodendrocyte progenitor process extension and survival. Annals of Neurology2008;63(1):61‐71. ">Miron 2008</a>; <a href="./references#CD009371-bbs2-0095" title="PaughS , CassidyM , HeH , MilstienS , Sim‐SelleyL , SpiegelS , et al. Sphingosine and its analog, the immunosuppressant 2‐Amino‐2‐(2‐[4‐octylphenyl]ethyl)‐1,3‐propanediol, interact with the CB1 cannabinoid receptor. Molecular Pharmacology2006;70:41–50. ">Paugh 2006</a>; <a href="./references#CD009371-bbs2-0096" title="PinschewerDD , OchsenbeinAF , OdermattB , BrinkmannV , HengartnerH , ZinkernagelRM . FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. Journal of Immunology2000;164:5761‐70. ">Pinschewer 2000</a>). </p> <p>Fingolimod was the first drug to gain approval as an oral treatment in the United States on 21 September, 2010, by the US Food and Drug Administration (FDA), "for the treatment of patients with relapsing forms of MS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability." Marketing authorisation was approved only for the 0.5 mg dose, due to a more favourable safety profile of this dosage compared to the 1.25 mg dose: "the higher dose, while exposing patients to more risk, did not expose patients to significantly increased efficacy,<i>"</i> and specific recommendations for monitoring patients and contraindications for use has been provided (<a href="./references#CD009371-bbs2-0060" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails2010; Vol. (accessed December 2015). ">FDA 2010</a>). </p> <p>The approval by the European Medicines Agency Committee for Medicinal Products for Human Use on 27 January, 2011 (<a href="./references#CD009371-bbs2-0058" title="European Medicines Agency. Committee for medicinal products for human use (CHMP). Gylenia summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002202/WC500104529.pdf(accessed December 2015). ">EMA 2011</a>), has been recently updated (<a href="./references#CD009371-bbs2-0057" title="European Medicines Agency. Gilenya : EPAR ‐ Summary for the public. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&amp;mid=WC0b01ac058004d5c1(accessed Decembre 2015). [ema.europa.eu/Find medicine/Humanmedicines/European Public Assessment Reports] ">EMA 2015</a>). Gilenya® is indicated as single disease modifying therapy in highly active RRMS for the following adult patient groups. </p> <p> <ol id="CD009371-list-0001"> <li> <p>Patients with high disease activity despite treatment with at least one disease modifying drug (DMD). These patients may be defined as those who have failed to respond to a full and adequate course (normally at least one year of treatment) of at least one DMD. Patients should have had at least one relapse in the previous year while on therapy, and have at least nine T2‐hyperintense lesions in cranial MRI or at least one gadolinium‐enhancing lesion. A “non‐responder” could also be defined as a patient with an unchanged or increased relapse rate or ongoing severe relapses, as compared to the previous year. </p> </li> <li> <p>Patients with rapidly evolving severe RRMS defined by two or more disabling relapses in one year, and with one or more gadolinium‐enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI. </p> </li> </ol> </p> </section> <section id="CD009371-sec-0027"> <h3 class="title" id="CD009371-sec-0027">Why it is important to do this review</h3> <p>Oral therapies have aroused lively interest amongst stakeholders, suggesting a new era of MS therapies with improved efficacy and more acceptable routes of administration. After approval of the use of fingolimod for the treatment of RRMS, different descriptive reviews have been published confirming the effectiveness of fingolimod in people with MS (<a href="./references#CD009371-bbs2-0052" title="DelSantoF , MarateaD , FaddaV , TrippoliS , MessoriA . Treatments for relapsing‐remitting multiple sclerosis: summarising current information by network meta‐analysis. European Journal of Clinical Pharmacology2011;68:441‐8. ">Del Santo 2011</a>; <a href="./references#CD009371-bbs2-0063" title="FreedmanMS . Treatment options for patients with multiple sclerosis who have a suboptimal response to Interferon‐ß therapy. European Journal of Neurology2014;21:377‐87. ">Freedman 2013</a>; <a href="./references#CD009371-bbs2-0069" title="HillertJ . In the coming year we should abandon Interferons and glatiramer acetate as first line therapy for MS: no. Multiple Sclerosis2013;19(1):26‐8. ">Hillert 2012</a>; <a href="./references#CD009371-bbs2-0070" title="HutchinsonM , FoxR , HavrdovaE , KurukulasuriyaN , SardaS , AgarwalS , et al. Efficacy and safety of BG‐12 (dimethyl fumarate) and other disease‐modifying therapies for the treatment of relapsing‐remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion2014;30(4):613‐27. ">Hutchinson 2014</a>; <a href="./references#CD009371-bbs2-0093" title="OhJ , O'ConnorPW . Safety, tolerability and efficacy of oral therapies for relapsing‐remitting multiple sclerosis. CNS Drugs2013;27:591‐609. ">Oh J 2013</a>), but also raising concerns about serious adverse events (<a href="./references#CD009371-bbs2-0080" title="LuE , WangBW , AlwanS , SynnesA , DahlgreenL , SadovnickA , et al. A review of safety‐related pregnancy data surrounding the oral disease‐modifying drugs for multiple sclerosis. CNS Drugs2014;28(2):89‐94. ">Lu 2013</a>; <a href="./references#CD009371-bbs2-0094" title="ParfenovV , SchluepM , Du PasquierR . Assessing risk of multiple sclerosis therapies. Journal of the Neurological Sciences2013;15:59‐65. ">Parfenov 2013</a>). A number of safety concerns emerged with post‐marketing surveillance, including serious infections and adverse cardiac effects (<a href="./references#CD009371-bbs2-0036" title="Agenzia Italiana del Farmaco(AIFA) . [Nota Informativa Importante sul primo caso di Leucoencefalopatia Multifocale Progressiva (PML) in un paziente con sclerosi multipla in trattamento con fingolimod]. http://www.agenziafarmaco.gov.it/it/content/nota‐informativa‐importante‐sul‐primo‐caso‐di‐leucoencefalopatia‐multifocale‐progressiva‐pml (accessed 10 December 2015). ">AIFA 2015</a>; <a href="./references#CD009371-bbs2-0057" title="European Medicines Agency. Gilenya : EPAR ‐ Summary for the public. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&amp;mid=WC0b01ac058004d5c1(accessed Decembre 2015). [ema.europa.eu/Find medicine/Humanmedicines/European Public Assessment Reports] ">EMA 2015</a>; <a href="./references#CD009371-bbs2-0093" title="OhJ , O'ConnorPW . Safety, tolerability and efficacy of oral therapies for relapsing‐remitting multiple sclerosis. CNS Drugs2013;27:591‐609. ">Oh J 2013</a>). The advantage of this therapy (as compared to other DMDs) has been questioned, suggesting need to reserve the use of fingolimod to patients who can be closely monitored. </p> <p>No systematic review of trials evaluating the benefit and safety of fingolimod has until now, been provided. By assessing and updating its benefit‐risk profile, the results of this review might clarify the use of fingolimod in clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009371-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-sec-0100">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009371-sec-0028"></div> <p>To assess the safety and benefits of fingolimod versus placebo, or other disease‐modifying drugs (DMDs), in reducing disease activity in people with relapsing‐remitting multiple sclerosis (RRMS). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009371-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-sec-0101">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009371-sec-0029"></div> <section id="CD009371-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009371-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) that studied fingolimod versus placebo or other approved disease‐modifying drugs (DMDs) in relapsing‐remitting multiple sclerosis (RRMS), irrespective of publication status and language. We excluded cross‐over studies. </p> </section> <section id="CD009371-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included participants of any age, gender and race affected by RRMS according to McDonald's diagnostic criteria (<a href="./references#CD009371-bbs2-0083" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnosis criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121‐7. ">Mc Donald 2001</a>; <a href="./references#CD009371-bbs2-0098" title="PolmanC , ReingoldS , EdanG , FilippiM , HartungH , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology2005;58:840–6. ">Polman 2005</a>; <a href="./references#CD009371-bbs2-0099" title="PolmanC , ReingoldS , BanwellB , ClanetM , CohenJ , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the MacDonald criteria. Annals of Neurology2011;69(2):292‐302. ">Polman 2011</a>). </p> </section> <section id="CD009371-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD009371-list-0002"> <li> <p>Fingolimod, any dose and route of administration, versus placebo without restriction of treatment duration. </p> </li> <li> <p>Fingolimod, any dose and route of administration, versus any other approved DMDs without restriction of treatment duration. </p> </li> </ol> </p> </section> <section id="CD009371-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD009371-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>1. Number of participants relapse‐free at six,12 and 24 months after randomisation and at the end of follow‐up. </p> <p>2. Number of participants free from disability worsening at 12, 24 and 36 months after randomisation and at the end of follow‐up. Disability worsening is defined as at least one point Expanded Disability Status Scale (EDSS) (<a href="./references#CD009371-bbs2-0077" title="KurtzkeJ . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983;33:1444‐52. ">Kurtzke 1983</a>) increase, or a 0.5 point increase if the baseline EDSS was &gt; 5.5, confirmed during two subsequent neurological examinations separated by at least 6 months' interval free of relapses. We considered separately studies that reported disability worsening defined using different criteria. </p> <p>3. Number of participants who withdrew from the study due to</p> <p>a) adverse events;</p> <p>b) serious adverse events, i.e. death, life‐threatening, hospitalisation, disability or permanent damage, congenital anomaly/birth defect (<a href="./references#CD009371-bbs2-0059" title="USFood , DrugAdministration . Safety. http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm(accessed December 2015). ">FDA 2013</a>). </p> </section> <section id="CD009371-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>4. Annualised relapse rate at six, 12 and 24 months after randomisation and at the end of follow‐up. </p> <p>5. Number of participants free from MRI gadolinium‐enhancing lesions at six, 12 and 24 months after randomisation and at the end of follow‐up. </p> <p>6. Mean change of total MRI T2 weighted lesion load at 12 and 24 months after randomisation and at the end of follow‐up. </p> <p>7. Quality of life measured by validated questionnaires such as MSQOL‐54 (<a href="./references#CD009371-bbs2-0106" title="VickreyBG , HaysRD , HarooniR , HarooniR , EllisonGW . A health‐related quality of life measure for multiple sclerosis. Quality of Life Research1995;4(3):187‐206. ">Vickrey 1995</a>). </p> </section> </section> </section> <section id="CD009371-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not apply any language restrictions.</p> <section id="CD009371-sec-0038"> <h4 class="title">Electronic searches</h4> <p>The Trials Search Co‐ordinator searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Specialised Trials Register, which contained trials identified from: </p> <p> <ol id="CD009371-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 2).</p> </li> <li> <p>MEDLINE (PubMed) (1966 to 15 February 2016).</p> </li> <li> <p>EMBASE (Embase.com) (1974 to 15 February 2016).</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost) (1981 to 15 February 2016). </p> </li> <li> <p>Latin American and Caribbean Health Science Information Database (LILACS) (Bireme) (1982 to 15 February 2016). </p> </li> <li> <p>Clinical trial registries: <a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov</a>. </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ol> </p> <p>The keywords for this review are listed in (<a href="./appendices#CD009371-sec-0085">Appendix 1</a>). </p> <p>Information on the Trial Register of the Review Group and details of search strategies used to identify trials can be found in the 'Specialised Register' section within the Cochrane Multiple Sclerosis and Rare Diseases of the CNS group <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/MS/frame.html" target="_blank">module</a>. </p> </section> <section id="CD009371-sec-0039"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD009371-list-0004"> <li> <p>Reference list of included studies and related reviews.</p> </li> <li> <p>Abstract books of the main MS meetings (European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), European Neurological Society (ENS), American Academy of Neurology (AAN)) for the last eight years. </p> </li> <li> <p>Contact with authors of primary studies, or drug manufacturers, or both.</p> </li> <li> <p>FDA reports on fingolimod (<a href="http://www.fda.gov/default.htm" target="_blank">www.fda.gov</a>). </p> </li> <li> <p>European Medicines Agency Committee for Medicinal Products for Human Use reports on fingolimod (<a href="http://www.ema.europa.eu/ema/" target="_blank">EMA</a>). </p> </li> </ol> </p> </section> </section> <section id="CD009371-sec-0040"> <h3 class="title" id="CD009371-sec-0040">Data collection and analysis</h3> <p>We performed the review and meta‐analyses following the recommendations of Cochrane (<a href="./references#CD009371-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We used Review Manager 5 to perform the analyses (<a href="./references#CD009371-bbs2-0100" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. ">RevMan 2015</a>). </p> <section id="CD009371-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Three review authors (LLM, IP, RP) independently identified trials and assessed titles and abstracts of the records retrieved by the search. We excluded irrelevant studies. We obtained the full text of the remaining studies to confirm inclusion. We resolved disagreements by discussion. </p> </section> <section id="CD009371-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LLM, IP) developed a data extraction form. Three review authors (LLM, IT, IP) extracted data on trial design, participants, interventions, and outcomes independently from each other. We resolved disagreements by discussion. </p> </section> <section id="CD009371-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (LLM, IT, IP) independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD009371-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We resolved any disagreement by discussion . </p> <p>We followed Cochrane's recommendations for assessing risk of bias for each included study (<a href="./references#CD009371-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We graded each potential source of bias as high, low or unclear (either lack of information or uncertainty over the potential for bias) and provided a quote for the study report together with a justification for our judgment in the "Risk of Bias" table. We assessed the risk of bias according the following domains: </p> <p> <ol id="CD009371-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>Outcome data were judged as low risk of bias when numbers and causes of losses to follow up were balanced between arms and when the percentage of participants lost to follow‐up was low (arbitrarily set at values lower than 15%). </p> <p>In addition, we defined the following two specific criteria to assess adverse events.</p> <p> <ol id="CD009371-list-0006"> <li> <p>Did the study provide a definition for severe adverse events?</p> </li> <li> <p>Did the researchers actively monitor for adverse events (low risk of bias) or did they simply provide spontaneous reporting of adverse events that arose (high risk of bias)? </p> </li> </ol> </p> </section> <section id="CD009371-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>The preset outcomes involved dichotomous, continuous and count data. We used the risk ratio (RR) with 95% confidence intervals (CIs) for dichotomous data, the weighted mean difference with 95% CIs for continuous data, and the rate ratio with 95% CI for count data. The rate ratio compares the rate of events in two groups by dividing one by the other. In order to avoid the assumption that the variability between the studies was exclusively because of a random sampling variation around a fixed‐effect, we used the random‐effects model. </p> </section> <section id="CD009371-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We performed a comparison with the parallel group maintaining the original randomisation of the study. In case of repeated observations, we tried to analyse each predefined outcome to reflect short‐term (six months), medium‐term (one year) and long‐term (&gt; 2 years) follow‐up. </p> </section> <section id="CD009371-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>In order to assess the effect of missing outcome data, we analysed data according to a likely scenario, i.e. we assumed that the treatment and control group participants who contributed to the missing data, both had experienced the outcome (relapse or disability). </p> </section> <section id="CD009371-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed between‐study heterogeneity both by inspection of graphical presentations using forest plots (<a href="./references#CD009371-bbs2-0055" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315:629‐34. ">Egger 1997</a>), and by calculating the I<sup>2</sup> statistic (significant if more than 50%) and the Chi<sup>2</sup> test (<a href="./references#CD009371-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> <section id="CD009371-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not perform a funnel plot because less than ten trials were included (<a href="./references#CD009371-bbs2-0055" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315:629‐34. ">Egger 1997</a>). </p> </section> <section id="CD009371-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses of primary and secondary outcomes using RevMan 5 (<a href="./references#CD009371-bbs2-0100" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2015. ">RevMan 2015</a>). </p> </section> <section id="CD009371-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were planned to answer specific questions, such as the effects about types of interventions (different dosages) or to investigate heterogeneous results (<a href="./references#CD009371-bbs2-0051" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Verion 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD009371-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>In the case where there was evidence of trials results heterogeneity, we planned to perform a sensitivity analysis to determine the effect of excluding trials with a high risk of bias. </p> <section id="CD009371-sec-0052"> <h5 class="title">'Summary of findings' table</h5> <p>We created two 'Summary of findings' tables comparing fingolimod at the approved dose of 0.5 mg daily; one versus placebo at 24 months after randomisation (<a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>), and one versus intramuscular interferon‐beta 1a at 12 months (<a href="./full#CD009371-tbl-0002">summary of findings Table 2</a>). In both 'Summary of findings' tables, we included five outcomes: number of participants relapse‐free; number of participants free from disability worsening ; number of withdrawals due to adverse events; annualised relapse rate; and number of participants free from MRI gadolinium‐enhancing lesions. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence. We followed methods and recommendations described in Section 11.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009371-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009371-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009371-sec-0053"></div> <section id="CD009371-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD009371-sec-0055"> <h4 class="title">Results of the search</h4> <p>Results of the search are described in a PRISMA flow chart (<a href="#CD009371-fig-0001">Figure 1</a>; <a href="./references#CD009371-bbs2-0085" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>). We assessed for eligibility 81 out of 481 records; 19 studies did not satisfy the inclusion criteria (<a href="./references#CD009371-sec-0092" title="">Characteristics of excluded studies</a>). We included a total of six RCTs (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>; <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>, <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>). Fifty‐six reports were ancillary to these primary studies. We found 10 ongoing trials; six are still ongoing (<a href="./references#CD009371-sec-0094" title="">Characteristics of ongoing studies</a>) and four have been completed and are awaiting classification (<a href="./references#CD009371-bbs2-0026" title="NCT01317004 . A 6‐month, randomized, active comparator, open‐label, multi‐center study to evaluate patient outcomes, safety and tolerability of fingolimod (FTY720) 0.5 mg/day in patients with relapsing remitting multiple sclerosis who are candidates for ms therapy change from previous disease modifying therapy (EPOC). clinicaltrials.gov/ct2/show/NCT01317004?term=NCT01317004&amp;rank=1 (accessed 22 February 2016). ">NCT01317004</a>; <a href="./references#CD009371-bbs2-0027" title="NCT01333501 . An 18‐month, open‐label, Rater‐blinded, randomized, multi‐center, active‐controlled, parallel‐group pilot study to assess efficacy and safety of fingolimod in comparison to interferon beta 1b in treating the cognitive symptoms associated with relapsing‐remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. clinicaltrials.gov/ct2/show/study/NCT01333501?term=NCT01333501&amp;rank=1 (accessed 22 February 2016). ">NCT01333501</a>; <a href="./references#CD009371-bbs2-0028" title="NCT01534182 . A 6‐month, randomized, active comparator, open‐label, multi‐center study to evaluate patient outcomes, safety and tolerability of (Fingolimod) 0.5 mg/day in patients with relapsing remitting multiple sclerosis who are candidates for multiple sclerosis (MS) therapy change from previous disease modifying therapy (DMT). clinicaltrials.gov/ct2/show/NCT01534182?term=NCT01534182&amp;rank=1 (accessed 10 December 2015). ">NCT01534182</a>; <a href="./references#CD009371-bbs2-0029" title="NCT01623596 . A 12‐month, Prospective, Randomized, Active‐controlled, Open‐label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First‐line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS). https://clinicaltrials.gov/ct2/show/study/NCT01623596?term=NCT01623596&amp;rank=1 22 February 2016. ">NCT01623596</a>) (<a href="./references#CD009371-sec-0093" title="">Characteristics of studies awaiting classification</a>). </p> <div class="figure" id="CD009371-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009371-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p> Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009371-sec-0056"> <h4 class="title">Included studies</h4> <p>The six trials were as follows.</p> <p> <ol id="CD009371-list-0007"> <li> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> (FREEDOMS II study) (phase III). </p> </li> <li> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> (TRANSFORMS study) (phase III). </p> </li> <li> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> (EPOC study) (phase IV). </p> </li> <li> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> (phase II). </p> </li> <li> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> (FREEDOMS study) (phase III). </p> </li> <li> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> (phase II). </p> </li> </ol> </p> <p>These trials were published between 2006 and 2014. Four studies compared fingolimod to placebo (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), one to intramuscular interferon beta‐1a (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>), and one to other DMDs (interferon beta‐1a, interferon beta‐1b, glatiramer acetate) (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>). Four studies used fingolimod at doses of 0.5 mg and 1.25 mg (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>). One study used doses of 1.25 mg and 5.0 mg (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>). One study evaluated only the dose of 0.5 mg (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>). Fingolimod was administered orally in all studies. </p> <p>The primary outcome was annualised relapse rate in three studies (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>); MRI measures of activity in two studies: number of gadolinium‐enhancing lesions (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>) and percentage of participants free from gadolinium‐enhancing lesions (<a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>); and treatment satisfaction in the other study (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>). Outcome measures and time points of assessment considered by each of the included trials are listed in <a href="#CD009371-tbl-0003">Table 1</a>. </p> <div class="table" id="CD009371-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome measures and time points</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Clinical outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MRI outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point assessment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.Annualised relapse rate </p> <p>2. Time to disability progression confirmed at 3 months</p> <p>3. Time to disability progression confirmed at 6 months</p> <p>4. Safety</p> <p>5. Time to first relapse</p> <p>6. Proportion of relapse‐free participants</p> <p>7. Change from baseline to the end of study on the MSFC score</p> <p>8. Quality of life using the Euro quality of life scale (EQ‐5D)</p> <p>9. Patient Reported Indices in Multiple Sclerosis</p> <p>10. Fatigue using the Modified Fatigue Impact Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.Percent brain‐volume change from baseline at 24 months</p> <p>2.Number and volume of gadolinium‐enhancing T1 lesions</p> <p>3. Number of new or newly enlarged T2 lesions</p> <p>4. Proportion of participants free of gadolinium‐enhancing T1 lesions</p> <p>5. Proportion of participants free of new or newly enlarged T2 lesions</p> <p>6. Proportion of participants free of new inflammatory activity (no gadolinium‐enhancing T1 lesions and no new or newly enlarged T2 lesions) </p> <p>7. Percentage change from baseline in volume of gadolinium‐enhanced T1 lesions</p> <p>8. Percentage change from baseline in volume of new or newly enlarged T2 lesions</p> <p>9. Brain volume</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Annualised relapse rate </p> <p>2. Progression of disability (confirmed at 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new or enlarged lesions on T2‐weighted scans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Treatment satisfaction </p> <p>2. Fatigue</p> <p>3. Depression</p> <p>4. Activities of daily living</p> <p>5. Health‐related Quality Of Life</p> <p>6, Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Number of participants remaining free of relapse</p> <p>2. Annualised relapse rate</p> <p>3, Time to the first relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.Number of gadolinium‐enhanced lesions per participant recorded on T1‐weighted MRI at monthly intervals for 6 months </p> <p>2.Total volume of gadolinium‐enhanced lesions per participants</p> <p>3. Proportion of participants with gadolinium‐enhanced lesions</p> <p>4. Total number of new lesion per participant on T‐weighted images</p> <p>5. Changes in lesion volume on T2‐weighted images</p> <p>6. Brain volume from baseline to month 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Annualised relapse rate </p> <p>2. Time to confirmed disability progression (confirmed after 3 months )</p> <p>3. Time to a first relapse</p> <p>4. Time to disability progression (confirmed after 6 months)</p> <p>5. Changes in the EDSS score</p> <p>6. Changes in the MSFC z score between baseline and 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Number of gadolinium‐enhancing lesions</p> <p>2. Proportion of participants free from gadolinium‐enhancing lesions</p> <p>3. Number of new or enlarged lesions on T2‐weighted MRI scans</p> <p>4. Proportion of participants free from new or enlarged lesions on T2‐weighted scan</p> <p>5. Volumes of hyperintense lesions on T2‐weighted scan</p> <p>6. Volumes of hypointense lesions on T1‐weighted scans</p> <p>7. Change in brain volume between baseline and 24 months</p> <p>8. Safety and tolerability measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of participants free from relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants free from gadolinium‐enhancing lesions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>EDSS</b> : Expanded Disability Status Scale; <b>MSFC</b>: Multiple Sclerosis Functional Composite </p> <p>The primary outcome of each study is underlined</p> </div> </div> <p>Confirmed relapse was defined as the occurrence of new symptoms, or worsening of previously stable or improving symptoms, and signs not associated with fever, lasting more than 24 hours. Symptoms had to appear at least 30 days after the onset of a preceding relapse (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), and had to be accompanied by an increase of at least half a point in the EDSS score (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>) or one point in at least one of the functions in the Kurtzke Functional System score (excluding bowel‐bladder and mental systems) (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>) or one point in each of two functions in the Kurtzke Functional Systems score, or two points in one of the functions in the Kurtzke Functional System score (excluding bowel–bladder or cerebral systems) (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>). </p> <p>Confirmed disability progression was defined as an increase of one point in the EDSS score (or 0.50 points if the baseline EDSS score was &gt; 5·0), that was<br/> confirmed three months later in the absence of relapse (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). Disability progression confirmed at six months was available in two studies at 24 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). Assessment of disability was performed using the Multiple Sclerosis Functional Composite (MSFC) score change in one study (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>). Disability progression was not considered by <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> and <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>. </p> <p>The treatment duration was six months in three trials (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>; <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), 12 months in one trial (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>), and 24 months in two trials (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). </p> <p>The <a href="./references#CD009371-sec-0091" title="">Characteristics of included studies</a> tables provide further details. </p> <p>All studies were sponsored by Novartis Pharma.</p> <section id="CD009371-sec-0057"> <h5 class="title">Description of participants</h5> <p>The overall population included in the six trials was 5152 participants with 3531 treated with fingolimod; 2061 with 0.5 mg daily, 1376 with 1.25 mg daily, and 94 with 5.0 mg daily. The comparison population included 1621 participants; 923 treated with placebo and 698 with intramuscular interferon beta‐1a or other DMDs. Enrolled participants were Caucasian, except in <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>, which included Japanese participants. Participants were affected by relapsing‐remitting multiple sclerosis (RRMS) in all studies, and secondary progressive multiple sclerosis (SPMS) in a small percentage in two studies; 11% in <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> and 2.3% in <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> (<a href="#CD009371-tbl-0004">Table 2</a>). </p> <div class="table" id="CD009371-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of the population included in the RCTs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Drugs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Female (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Course of disease of RR‐SP (%) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age, years, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean EDSS score (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Disease duration, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pre‐1 year number of relapses, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Percentage of pre‐study treatment‐naive participants </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Percentage of participants with MRI enhancing lesions </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean lesion volume on T2‐weighted images (mm3 ) (SD)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40·1 (8·4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2·2 (1·5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10·6 (7·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1·5 (0·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5553 (7841)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40·6 (8·4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2·2 (1·4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10·4 (8·0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1·4 (0·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5484 (8000)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40·9 (8·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2·3 (2·0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10·8 (8·2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1·5 (1·0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4936 (7286)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1a (Avonex)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.0 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19 (1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4924 (5711)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.7 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.24 (1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 (6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5170 (6642)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.8 (8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21 (1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3 (6.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5085 (5962)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DMD<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.1 (9.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 (1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7 (8.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.0 (9.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 (1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1 (8.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 ‐ 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.1 (19‐56)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (0.0‐6.5)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (0.2‐28.2)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 (0‐5)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8805 (123‐62,218)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 ‐ 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.0 (19‐60)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (0.0‐6.0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 (0.3‐50.2)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0‐5)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,219 (293‐104,504)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 5.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 ‐ 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.3 (18‐59)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (0.0‐6.0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 (0.5‐42.2)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0‐4)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8722 (349‐70,218)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.2 (8.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (0.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6162 (7085)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.6 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 (6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6128 (7623)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.4 (8.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6829 (8491)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0 (8.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (7.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6 (22.6)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.7 ‐ 5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0 (9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (6.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.4 (22.7)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.2 ‐ 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.0 (9.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.7 (23.3)**</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>DMD:</b> disease‐modifying drug;<b>EDSS</b> : Expanded Disability Status Scale; <b>MRI</b> : magnetic resonance imaging; <b>NR</b> : not reported; <b>RR:</b> relapsing‐remitting; <b>SD</b> : standard deviation; <b>SP:</b> secondary progressive </p> <p>* Range (SD was not provided)<br/> ** Number of T2 lesions (volume was not provided)<br/> <sup>§</sup> interferon beta‐1b (Extavia® or Betaseron®) 0.25 mg injected subcutaneously every other day (46 participants); interferon beta‐1a (Avonex®) 30 μg intramuscular injected once a week (60 participants); interferon beta‐1a (Rebif®) 22 μg or 44 μg injected subcutaneously three times a week (65 participants); or glatiramer acetate (Copaxone®) 20 mg injected subcutaneously once‐daily (92 participants) </p> </div> </div> <p>The inclusion criteria were similar among studies. Previous treatment with immunomodulating agents for at least six months were required in <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>, and accepted in all other studies if the suspension occurred more than three months before trial onset (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), not specified in <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>. </p> <p>Exclusion criteria were similar and included clinically significant systemic diseases, macular oedema (not specified for <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>), and diabetes (not specified for <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> and <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>). Participants treated with immunosuppressants were excluded (<a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>), they had to interrupt treatment in the six months prior to randomisation (<a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), interrupt azathioprine or methotrexate within six months, cyclophosphamide within 12 months, mitoxantrone or cladribine within 24 months (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>), and natalizumab at least six months before randomisation (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>). Two studies specified as exclusion criteria the presence of cardiac abnormalities or leukopenia or lymphopenia (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>). Participants with varicella zoster immunoglobulin G (IgG) antibody negative at screening were excluded in three studies (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>). </p> <p>The baseline clinical characteristics were homogeneous in term of age (ranging from 35.0 to 38.3 years), disability score (EDSS 1.8 to 2.7), disease duration (7.1 to 9.5 years), and mean relapse number in the year before randomisation (1.2 to 1.7). Percentage of prestudy treatment‐naive participants were different among studies, ranging from 0% to 60.4%. MRI enhancing lesions were detected in 31% to 49% of the participants, while the volume of MRI T2‐weighted lesions at baseline ranged from 4924 mm<sup>3</sup> to 10,219 mm<sup>3</sup> (<a href="#CD009371-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD009371-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded 18 studies because type of participants (three studies), design (seven studies) or intervention (one study) did not meet our inclusion criteria, five studies were not original articles (reporting pooled data of trials), and two studies were overviews (<a href="./references#CD009371-sec-0092" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD009371-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>We evaluated risk of bias separately for benefit estimate (<a href="./references#CD009371-sec-0091" title="">Characteristics of included studies</a>), and adverse events monitoring (<a href="#CD009371-tbl-0005">Table 3</a>). </p> <div class="table" id="CD009371-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Methods of adverse events monitoring</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the researchers actively monitor for adverse events (AEs) (low risk of bias) or did they simply provide spontaneous reporting of AEs that arose (high risk of bias)?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the authors define serious AEs (SAEs) according to an accepted international classification and report the number of SAEs?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"We did extensive safety and tolerability assessments, in part as a response to preclinical safety concerns raised by the FDA and additional safety areas of interest identified in previous phase 2 and earlier clinical studies. We also recorded adverse events, serious adverse events, serious adverse events of special interest, 24 h Holter electrocardiography (ECG) post first‐dose and at 3 months, first‐dose bradycardia events, infections, laboratory tests, vital signs, ECG, echocardiography, pulmonary function.</i> tests, chest high‐resolution CT,<i>chest radiographs, ophthalmic examinations, including serial optical coherence tomography, and dermatological assessments." Clinical assessments were performed at screening and at randomisation (baseline), and study visits, including safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomisation</i>" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>"We also recorded adverse events, serious adverse events, serious adverse events of special interest, 24 h Holter electrocardiography (ECG) post fist‐dose and at 3 months, first‐dose bradycardia events, infections, laboratory tests, vital signs, ECG, echocardiography, pulmonary function</i> tests, chest high‐resolution CT,<i>chest radiographs, ophthalmic examinations, including serial optical coherence tomography, and dermatological assessments"</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>An independent data and safety monitoring board evaluated overall safety in the fingolimod phase 3 program</i> " and <i>"Safety assessments were conducted during screening, at baseline, and at months 1, 2, 3, 6, 9, and 12</i>" (pg 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs were predefined per standard criteria (death, life‐threatening event, persistent disability, congenital defect, unplanned hospitalisation, or otherwise medically significant) (<a href="./references#CD009371-bbs2-0060" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails2010; Vol. (accessed December 2015). ">FDA 2010</a> Clinical review of safety pg 151) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>"Safety and tolerability (secondary study objectives) were assessed via reporting of</i> <br/> <i>adverse events (AEs) and through physical examinations (ophthalmologist</i> <br/> <i>examinations, and evaluations of vital signs, chest x‐rays, and electrocardiograms</i> <br/> <i>[ECGs]), laboratory evaluations (measurement of hematology parameters, chemistry, urinalysis, serology, and lymphocyte counts)"</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>An independent external data and safety monitoring board evaluated adverse events and other safety data" and "Adverse events were assessed and reported at each visit (scheduled and unscheduled) by the treating physicians. Laboratory evaluations were undertaken at a central laboratory". "Vital signs were obtained at each visit, and laboratory and hematologic measures were obtained at baseline, day 1, and months 1,3,6,9, and 12. Electrocardiograms were obtained at baseline, on days 1 and 7, and at months 1,3,6,12, and 24 hour Holter electrocardiographic monitoring was performed at selected sites at baseline, day 1, and month 3. Pulmonary function tests... were performed at screening and months 6 and 12</i>" (pg 1126) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>An independent data and safety monitoring board evaluated the safety</i> " and "S<i>tudy visits, including safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomization</i>" (pg 389) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs were predefined per standard criteria (death, life‐threatening event, persistent disability, congenital defect, unplanned hospitalisation, or otherwise medically significant) (<a href="./references#CD009371-bbs2-0060" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails2010; Vol. (accessed December 2015). ">FDA 2010</a> Clinical review of safety pg 151) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>Adverse events, serious adverse events assessments were conducted at screening, baseline, days 1 and 15, and months 1,2,3,4,5 and 6" (pg 2) and "Safety assessment included recording of AEs, SAEs, hematology values, vital signs, results of dermatological and ophthalmological examinations and results of pulmonary and liver function tests</i>" (Supplementary data online appendix) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event; CT: chest tomography; ECG: electrocardiography; FDA: Food and Drug Administration; SAE: serious adverse event </p> </div> </div> <section id="CD009371-sec-0060"> <h4 class="title">Allocation</h4> <p>We considered the method used to generate a random sequence and conceal allocation to be at low risk of bias in all trials except one; we judged <a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> to be at unclear risk of bias. </p> </section> <section id="CD009371-sec-0061"> <h4 class="title">Blinding</h4> <p>All included trials, except one open‐label trial were described as double‐blinded (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>). The drug in the treatment group was reported as identical in appearance to the drug in the control group. Assessors of clinical and radiological outcomes were reported as unaware of participants' assignment. We judged <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> to be at high risk of bias and the other trials to be at low risk of bias for blinding. </p> </section> <section id="CD009371-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>All trials provided a sufficient description of follow‐up and withdrawals. We judged three trials to be at high risk of attrition bias because significant differences in reasons of dropouts between treated and control groups were found ( <a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> ; <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> ; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). </p> </section> <section id="CD009371-sec-0063"> <h4 class="title">Selective reporting</h4> <p>We judged all trials to be at low risk of bias apart from <a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>, which we judged to be at unclear risk of bias as it did not report on clinically relevant results. </p> </section> <section id="CD009371-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>All trials were sponsored by Novartis Pharma. We judged four trials to be at high risk of bias because the study sponsor participated in conducting the study, or data analysis and some study co‐authors were affiliated to the pharmaceutical company (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>; <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>) . </p> <p>Further details are provided in relevant sections of the <a href="./references#CD009371-sec-0091" title="">Characteristics of included studies</a> tables and are presented as the 'Risk of bias' summary and 'Risk of bias' graph (<a href="#CD009371-fig-0002">Figure 2</a>; <a href="#CD009371-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD009371-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009371-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD009371-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009371-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD009371-sec-0065"> <h5 class="title">Methods of adverse events monitoring</h5> <p>We judged the risk of bias regarding methods of adverse events monitoring to be low for all studies. We judged the risk of bias regarding methods of serious adverse events monitoring to be unclear for the <a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> and for the <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> studies and low for four others (<a href="#CD009371-tbl-0005">Table 3</a>). </p> </section> </section> </section> <section id="CD009371-sec-0066"> <h3 class="title" id="CD009371-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD009371-tbl-0001"><b>Summary of findings for the main comparison</b> Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis</a>; <a href="./full#CD009371-tbl-0002"><b>Summary of findings 2</b> Fingolimod 0.5 mg versus interferon beta‐1a for relapsing‐remitting multiple sclerosis</a> </p> <p>We defined two main comparisons, one evaluating the effect of fingolimod versus placebo and one evaluating the effect of fingolimod versus intramuscular IFN‐beta 1a or other DMDs. For each comparison, we considered the effect of fingolimod separately for the approved dose (0.5 mg) and the other treatment schedules (1.25 mg and 5.0 mg). </p> <p>We reported the main results concerning benefit and withdrawals due to adverse events of fingolimod at the approved dose of 0.5 mg compared to placebo at 24 months in <a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a> and compared to intramuscular interferon beta‐1a at 12 months in <a href="./full#CD009371-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD009371-sec-0067"> <h4 class="title">Fingolimod compared to placebo</h4> <section id="CD009371-sec-0068"> <h5 class="title">Primary Outcomes</h5> <p>The number of participants who were free from relapses during treatment with fingolimod 0.5 mg compared to placebo were retrieved from one trial (114 participants = 2.2%) at six months (<a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), and two trials (1556 participants =30%) at 24 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). At six months, there was a slight non‐significant benefit (risk ratio (RR) 1.22, 95% confidence interval (CI) 0.96 to 1.54) (<a href="./references#CD009371-fig-0006" title="">Analysis 1.1</a>). At 24 months the overall results indicated a benefit of fingolimod (RR 1.44, 95% CI 1.28 to 1.63; moderate quality evidence) (<a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD009371-fig-0008" title="">Analysis 1.3</a>). The higher doses were effective at six months at 1.25 mg (RR 1.27, 95% CI 1.11 to 1.45) and 5 mg (RR 1.30, 95% CI 1.10 to 1.53) (<a href="./references#CD009371-fig-0006" title="">Analysis 1.1</a>), and at 24 months at 1.25 mg (RR 1.51, 95% CI 1.29 to 1.76) (<a href="./references#CD009371-fig-0008" title="">Analysis 1.3</a>). </p> <p>Data from two trials were available to calculate the number of participants without disability worsening during the first 24 months of treatment with fingolimod compared to placebo (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). The results indicated little or no difference of fingolimod at 0.5 mg (RR 1.07, 95% CI 1.02 to 1.11; low quality evidence) (<a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>). Similar results were found when fingolimod was used at 1.25 mg (RR 1.08, 95% CI 1.03 to 1.12) (<a href="./references#CD009371-fig-0010" title="">Analysis 2.2</a>). </p> <p>The number of participants who withdrew from the study because of adverse events with 0.5 mg of fingolimod compared to placebo was retrieved from two trials during the first six months (RR 2.00, 95% CI 0.53 to 7.61) (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>: <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#CMP-003.01" target="_blank">Analysis 3.1</a>); and two trials during the first 24 months of treatment (RR 1.42, 95% CI 0.89 to 2.25; very low quality evidence) (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#CMP-003.03" target="_blank">Analysis 3.3</a>). The risk of discontinuing 1.25 mg of fingolimod due to adverse events compared to placebo significantly increased at 24 months (RR 1.93, 95% CI 1.48 to 2,52) (<a href="./references#CD009371-fig-0013" title="">Analysis 3.3</a>). </p> <p>Detailed descriptive data on the type of adverse events, as reported in the primary studies, are provided in <a href="#CD009371-fig-0004">Figure 4</a>. It should be noted that infections, hypertension, and abnormal liver tests were more frequent in the fingolimod group than in the placebo group. </p> <div class="figure" id="CD009371-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="N, number of patients; n, number of events.Significant differences (based on Fisher exact test) are reported in red." data-id="CD009371-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>N, number of patients; n, number of events.</p> <p>Significant differences (based on Fisher exact test) are reported in red.</p> </div> </div> </div> <p>The number of participants who withdrew because of serious adverse events were available from two trials at six months (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), and two trials at 24 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>). No difference was found between placebo and fingolimod administered at 0.5 mg and 1.25 mg (<a href="./references#CD009371-fig-0014" title="">Analysis 3.4</a>; <a href="./references#CD009371-fig-0016" title="">Analysis 3.6</a>). A significant increased risk of discontinuation was found for fingolimod 5.0 mg versus placebo at six months (RR 2.77, 95% CI 1.04 to 7.38) (<a href="./references#CD009371-fig-0014" title="">Analysis 3.4</a>). </p> <p>Detailed descriptive data on the type of serious adverse events, as reported in the primary studies, are provided in <a href="#CD009371-fig-0005">Figure 5</a>. It should be noted that infections, basal‐cell carcinoma, and atrioventricular blocks were more frequent in the fingolimod group than in the placebo group. </p> <div class="figure" id="CD009371-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="N, number of patients; n, number of events.* One case of basal‐cell carcinoma was not reported as a serious adverse event by the site investigator (Calabresi 2014).Significant differences (based on Fisher exact test) are reported in red." data-id="CD009371-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>N, number of patients; n, number of events.</p> <p>* One case of basal‐cell carcinoma was not reported as a serious adverse event by the site investigator (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>). </p> <p>Significant differences (based on Fisher exact test) are reported in red.</p> </div> </div> </div> <p>The results regarding data analysed according to a likely scenario did not add any additional information (data not reported). </p> </section> <section id="CD009371-sec-0069"> <h5 class="title">Secondary outcomes</h5> <p>The annualised relapse rate was evaluated by two trials at six months (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>), and two trials at 24 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>): at these time points the results favoured fingolimod 0.5 mg compared to placebo at six months (rate ratio 0.51, 95% CI 0.26 to 0.99; <a href="./references#CD009371-fig-0017" title="">Analysis 4.1</a>) and 24 months (rate ratio 0.50, 95% CI 0.40 to 0.62; moderate quality evidence) (<a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD009371-fig-0019" title="">Analysis 4.3</a>). Similar data were found for higher doses (<a href="./references#CD009371-fig-0017" title="">Analysis 4.1</a>, <a href="./references#CD009371-fig-0019" title="">Analysis 4.3</a>). </p> <p>The number of participants free from MRI gadolinium‐enhancing lesions was evaluated by four trials at six months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a>; <a href="./references#CD009371-fig-0020" title="">Analysis 5.1</a>), two trials at 12 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-fig-0021" title="">Analysis 5.2</a>), and two trials at 24 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>; <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>; <a href="./references#CD009371-fig-0022" title="">Analysis 5.3</a>). We found better results for fingolimod doses compared to placebo at each time point: fingolimod 0.5 mg at six months (RR 1.42, 95% CI 1.33 to 1.51); 0.5 mg at 12 months (RR 1.39, 95% CI 1.30 to 1.48); and 0.5 mg at 24 months (RR 1.36, 95% CI 1.27 to 1.45; low quality evidence) (<a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The mean change of MRI T2‐weighted lesion load was evaluated by one trial at 12 months (<a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>): the results favoured fingolimod 0.5 mg compared to placebo (mean difference (MD) ‐15.30, 95% CI ‐24.34 to ‐6.26); similar data were found when fingolimod was used at 1.25 mg for 12 months (<a href="./references#CD009371-fig-0023" title="">Analysis 6.1</a>). At 24 months the results also favoured fingolimod 0.5 mg compared to placebo (MD ‐20.43, 95% CI ‐34.03 to ‐6.83); similar data were found for fingolimod 1.25 mg (<a href="./references#CD009371-fig-0024" title="">Analysis 6.2</a>). </p> <p>Quality of life was measured by the Hamburg Quality of Life Questionnarie in one trial at six months (<a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a>), and by the Euro quality of life scale (EQ‐5D) in one trial at 24 months (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>). No differences were found between fingolimod and placebo in either study (<a href="./references#CD009371-fig-0025" title="">Analysis 7.1</a>; <a href="./references#CD009371-fig-0026" title="">Analysis 7.2</a>). </p> </section> </section> <section id="CD009371-sec-0070"> <h4 class="title">Fingolimod compared to intramuscular interferon beta‐1a or other DMDs</h4> <section id="CD009371-sec-0071"> <h5 class="title">Primary Outcomes</h5> <p>Data from one trial were available to evaluate the primary outcomes during the first 12 months of treatment with fingolimod 0.5 mg compared to intramuscular interferon beta‐1a (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>). </p> <p>The overall results (RR 1.18, 95% CI 1.09 to 1.27; moderate quality evidence) indicated a slight advantage for fingolimod 0.5 mg in favouring freedom from relapse (<a href="./full#CD009371-tbl-0002">summary of findings Table 2</a>). Similar results were found when fingolimod was used at 1.25 mg (RR 1.15, 95% CI 1.06 to 1.24) (<a href="./references#CD009371-fig-0007" title="">Analysis 1.2</a>). </p> <p>The results indicated no difference in favouring freedom from disability worsening at 12 months between fingolimod 0.5 mg and intramuscular interferon beta‐1a (RR 1.02, 95% CI 0.99 to 1.06; low quality evidence) (<a href="./full#CD009371-tbl-0002">summary of findings Table 2</a>). Similar results were found when fingolimod was used at 1.25 mg (RR 1.01, 95% CI 0.98 to 1.05) (<a href="./references#CD009371-fig-0009" title="">Analysis 2.1</a>). </p> <p>Compared to intramuscular interferon beta‐1a, the number of participants who withdrew due to adverse events was higher, but not significant for fingolimod 0.5 mg (RR 1.51, 95% CI 0.81 to 2.80; moderate quality evidence) (<a href="./full#CD009371-tbl-0002">summary of findings Table 2</a>). Significant risk was found when used at 1.25 mg (RR 2.69, 95% CI 1.54 to 4.72) (<a href="./references#CD009371-fig-0012" title="">Analysis 3.2</a>). </p> <p>Compared to intramuscular interferon beta‐1a, the number of participants who withdrew due to serious adverse events was higher, but not significant for fingolimod 0.5 mg (RR 1.21, 95% CI 0.72 to 2.02), and significantly higher for fingolimod 1.25 mg (RR 1.85, 95% CI 1.15 to 2.96) (<a href="./references#CD009371-fig-0015" title="">Analysis 3.5</a>). </p> <p>Data from one trial were available to calculate the number of participants who withdrew due to adverse events during the first six months (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>): the RR was significantly higher for fingolimod 0.5 mg compared to other DMDs (RR 3.21, 95% CI 1.16 to 8.86) (<a href="./references#CD009371-fig-0011" title="">Analysis 3.1</a>). </p> <p>Data from the same trial showed that the number of participants who withdrew due to serious adverse events were higher with fingolimod 0.5 mg compared to other DMDs (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>), but the result was not significant (RR 2.71, 95% CI 0.83 to 8.88) (<a href="./references#CD009371-fig-0014" title="">Analysis 3.4</a>). </p> <p>Detailed descriptive data on the type of adverse and serious adverse events are provided in <a href="#CD009371-fig-0004">Figure 4</a> and <a href="#CD009371-fig-0005">Figure 5</a>, respectively. The higher incidence of adverse events in fingolimod versus interferon beta‐1a, suggests lower tolerability for fingolimod. It should be noted that hypertension was more frequent in participants taking fingolimod, and depression was more frequent in the interferon beta‐1a group. </p> </section> <section id="CD009371-sec-0072"> <h5 class="title">Secondary outcomes</h5> <p>The annualised relapse rate was evaluated by one trial at 12 months (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>). A significant benefit for fingolimod 0.5 mg (RR 0.48, 95% CI 0.34 to 0.70) and fingolimod 1.25 mg (RR 0.61, 95% CI 0.47 to 0.78) doses compared to intramuscular interferon beta‐1a was observed (<a href="./references#CD009371-fig-0018" title="">Analysis 4.2</a>). </p> <p>The number of participants free from MRI gadolinium‐enhancing lesions at 12 months was evaluated by the same trial (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>); a slight advantage for fingolimod 0.5 mg (RR 1.12, 95% CI 1.05 to 1.19) and fingolimod 1.25 mg (RR 1.13, 95% CI 1.06 to 1.20) compared to intramuscular interferon beta‐1a was observed (<a href="./references#CD009371-fig-0021" title="">Analysis 5.2</a>). </p> <p>The mean change of MRI T2‐weighted lesion load at 12 months was evaluated by the same trial (<a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>); we found no significant reduction for fingolimod 0.5 mg (MD ‐0.50, 95% CI ‐6.32 to 5.32) and fingolimod 1.25 mg (MD ‐3.70, 95% CI ‐9.18 to 1.78) doses compared to intramuscular interferon beta‐1a (<a href="./references#CD009371-fig-0023" title="">Analysis 6.1</a>). </p> <p>Quality of life was measured at six months by the FS36 questionnaire in participants treated with fingolimod 0.5 mg compared to DMDs (<a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a>). The results favoured fingolimod (<a href="./references#CD009371-fig-0025" title="">Analysis 7.1</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009371-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009371-sec-0073">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009371-sec-0109">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009371-sec-0073"></div> <section id="CD009371-sec-0074"> <h3 class="title" id="CD009371-sec-0074">Summary of main results</h3> <p>Six RCTscontributed to this review. The overall population included 5152 participants; 3531 were randomly assigned to fingolimod (2061 of them treated with the approved dose of 0.5 mg daily) and 1621 controls, 923 treated with placebo and 698 with intramuscular interferon beta‐1a or other DMDs. The treatment duration was six months in three trials (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#STD-Fox-2014" target="_blank">Fox 2014</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#STD-Kappos-2006" target="_blank">Kappos 2006</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#STD-Saida-2012" target="_blank">Saida 2012</a>),12 months in one trial (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#STD-Cohen-2010a" target="_blank">Cohen 2010a</a>), and 24 months in two trials (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#STD-Calabresi-2014" target="_blank">Calabresi 2014</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=10049511630492405763100505125143%26versionPK1=z1511020949282148752647066672427%26versionPK2=z1512111341476708642916760143478#STD-Kappos-2010" target="_blank">Kappos 2010</a>). All studies were sponsored by Novartis Pharma. </p> <p>Fingolimod administered at the approved dose of 0.5 mg orally once‐daily is effective in increasing the number of people free from relapse (moderate quality of evidence) and from MRI gadolinium‐enhancing lesions (low quality of evidence), and in reducing the annualised relapse rate (moderate quality of evidence) at 24 months compared to placebo. A benefit on prevention of disability worsening was not observed (low quality of evidence). The risk of withdrawal due to adverse events was not significant (very low quality of evidence) (<a href="./full#CD009371-tbl-0001">summary of findings Table for the main comparison</a>). Furthermore, MRI T2‐weighted lesion load changes at 12 and 24 months favour fingolimod versus placebo. </p> <p>A slight advantage of fingolimod at a dose of 0.5 mg compared to intramuscular interferon beta‐1a in increasing freedom from relapse and from gadolinium‐enhancing lesions at 12 months was observed (moderate quality of evidence). A benefit was found for other measures of clinical activity (relapse rate: moderate quality of evidence). No difference between the two active treatments was found regarding prevention of disability worsening at 12 months (low quality of evidence). The risk of withdrawal due to adverse events was not significant (moderate quality of evidence) (<a href="./full#CD009371-tbl-0002">summary of findings Table 2</a>) despite a worst tolerability due to the higher incidence of adverse events. Furthermore, no difference was observed regarding the mean change of MRI T2‐weighted lesion load at 12 months. </p> </section> <section id="CD009371-sec-0075"> <h3 class="title" id="CD009371-sec-0075">Overall completeness and applicability of evidence</h3> <p>All studies assessed the clinical and MRI outcomes selected for this review, except <a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> who included only patient‐oriented outcomes. Participants were adults with relapsing‐remitting multiple sclerosis (RRMS), a high prestudy relapse frequency, low disability and disease duration over five years (<a href="#CD009371-tbl-0004">Table 2</a>). </p> <p>The following four points, relevant for clinical practice, should be highlighted:</p> <p> <ol id="CD009371-list-0008"> <li> <p>Measures of treatment response.</p> </li> <li> <p>Worsening of disability.</p> </li> <li> <p>Comparison with other active treatments.</p> </li> <li> <p>Impact on quality of life.</p> </li> </ol> <ol id="CD009371-list-0009"> <li> <p>The assessment of disease activity has been recently incorporated to redefine MS disease phenotypes (<a href="./references#CD009371-bbs2-0081" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ , et al. Defining the clinical course of multiple sclerosis. The 2013 revisions. Neurology2014;83:278–86. ">Lublin 2014</a>). On the other hand, treatment expectations have evolved to include potential remission from MS symptoms to freedom from disease activity. We have chosen the number of participants without clinical (relapse and worsening of disability) and MRI (gadolinium‐enhancing lesions) events, as separate outcome measures. This is to underline the possible benefit from treatment. We have included a further MRI endpoint (total volume of abnormal T2‐hyperintensity) as a marker of disease severity (<a href="./references#CD009371-bbs2-0078" title="LaveryAM , VerheyLH , WaldmanAT . Outcome measures in relapsing‐remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Multiple Sclerosis International2014;2014:1‐13. [ID 262350] ">Lavery 2014</a>). We have not included composite measures, such as, 'no evidence of disease activity' (NEDA), as they are not yet accepted as a primary outcome, and are of uncertain prognostic value (<a href="./references#CD009371-bbs2-0065" title="GiovannoniG , TurneraB , GnanapavanaS , OffiahcC , SchmiereraK , MartaM . Is it time to target no evident disease activity(NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders 215;4:329–33. ">Giovannoni 2015</a>; <a href="./references#CD009371-bbs2-0102" title="RotsteinDL , HealyBC , MalikMT , ChitnisT , WeinerHL . Evaluation of no evidence of disease activity in a 7‐year longitudinal multiple sclerosis cohort. JAMA2015;72(2):152‐8. ">Rotstein 2015</a>). Only post–hoc analysis concerning NEDA on pooled fingolimod trial populations has been published (<a href="./references#CD009371-bbs2-0073" title="KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. ">Kappos 2015b</a>; <a href="./references#CD009371-bbs2-0089" title="NixonR , BergvallN , TomicD , SfikasN , CutterG , GiovannoniG . No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing–remitting multiple sclerosis. Advances in Therapy2014;31:1134–54. ">Nixon 2014</a>), and useful data in the primary studies were lacking. </p> </li> <li> <p>We did not find substantial evidence that fingolimod modified the risk of disability worsening, in spite of efficacy for inflammatory disease activity. We considered disability worsening as confirmed at six months follow‐up. Using less stringent criteria (three months), <a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> and <a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> found that fingolimod was effective over the 24‐month period; however, this result may be related to reversible relapse‐related disability accrual. Dissociation between relapse and disability worsening is well documented during the natural course of the disease (<a href="./references#CD009371-bbs2-0103" title="ScalfariA , NeuhausA , DegenhardtA , RiceP , MuraroP , DaumerM , et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long‐term disability. Brain2010;133:1914–29. ">Scalfari 2010</a>; <a href="./references#CD009371-bbs2-0104" title="ScalfariA , NeuhausA , DaumerM , DelucaGC , MuraroPA , EbersGC . Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA2013;70(2):214‐22. ">Scalfari 2013</a>). On the other hand, meaningful changes might be difficult to detect using the outcomes currently approved to measure clinical disability, mainly in the early stages of the disease, and after a short treatment period (<a href="./references#CD009371-bbs2-0045" title="CohenJA , ReingoldSC , PolmanCH , WolinskyJW , International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinicaltrials: current status and future prospects. Lancet Neurology2012;11(5):467–76. ">Cohen 2012</a>; <a href="./references#CD009371-bbs2-0078" title="LaveryAM , VerheyLH , WaldmanAT . Outcome measures in relapsing‐remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Multiple Sclerosis International2014;2014:1‐13. [ID 262350] ">Lavery 2014</a>). A divergent effect might also occur when different pathogenetic mechanisms occur (degenerative and inflammatory). In fact, no effect on progressive MS has been reported (<a href="./references#CD009371-bbs2-0021" title="LublinF , MillerDH , FreedmanMS , CreeBA , WolinskyJS , WeinerH , et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double‐blind, placebo‐controlled trial. Lancet 2016 Jan 27 [Epub ahead of print]. ">Lublin 2016</a>; <a href="./references#CD009371-bbs2-0091" title="Novartis . Novartis provides on fingolimod phase III trial in primary progressive MS (PPMS). https://www.novartis.com/news/media‐releases/novartis‐provides‐update‐fingolimod‐phase‐iii‐trial‐primary‐progressive‐ms‐ppms (accessed 18 January 2016). ">Novartis 2016</a>). </p> </li> <li> <p>We only included one comparison concerning clinical and MRI outcomes in this review, i.e. fingolimod versus intramuscular interferon beta‐1a. We will evaluate ongoing trials of fingolimod compared to other approved DMDs in future updates of the review. </p> </li> <li> <p>We did not find any benefit for fingolimod for quality of life in people with RRMS over two years of therapy, in comparison to placebo (<a href="./references#CD009371-fig-0026" title="">Analysis 7.2</a>). This result is relevant considering the expectation of oral therapy after the era of injectable drugs; following the introduction of fingolimod, patients with RRMS have switched to this drug rather than any other therapies, and they did so for convenience (<a href="./references#CD009371-bbs2-0107" title="Warrender‐SparkesM , SpelmanT , IzquierdoG , TrojanoM , LugaresiA , Grand’MaisonF , et al. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis 2015 Jul 21 [Epub ahead of print]. ">Warrender‐Sparkes 2015</a>). Type of scales and assessment methods used to measure quality of life in the included studies might have influenced the estimated effect of fingolimod for this outcome (<a href="#CD009371-tbl-0003">Table 1</a>). </p> </li> </ol> </p> <p>The following limitations of the review need to be highlighted: .</p> <p> <ol id="CD009371-list-0010"> <li> <p>The duration of the included trials was equal to or less than 24 months. Extension studies have been reported, but in most of them placebo‐treated participants switched to the fingolimod group. We excluded open‐label extension studies in this review. </p> </li> <li> <p>The influence of patients' baseline characteristics on the effect of fingolimod was not explored due to lack of useful data in the included trials. Contradictory data are available in the literature. For example, one article reported that response to fingolimod was associated with patients' baseline high relapse frequency (<a href="./references#CD009371-bbs2-0093" title="OhJ , O'ConnorPW . Safety, tolerability and efficacy of oral therapies for relapsing‐remitting multiple sclerosis. CNS Drugs2013;27:591‐609. ">Oh J 2013</a>). A post‐hoc subgroup analysis of the FREEDOM study (<a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a>), reported lack of benefit of fingolimod on the relapse rate for people with MS older than 40 years and on disability worsening for those with baseline expanded disability status scale (EDSS) less than 3.5 score (<a href="./references#CD009371-bbs2-0053" title="DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420‐8. ">Devonshire 2012</a>). Fingolimod was found to be superior to intramuscular interferon beta‐1a in all subgroups defined by demographic factors or baseline disease characteristics (<a href="./references#CD009371-bbs2-0046" title="CohenJ , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. ">Cohen 2013</a>). Another study reported that fingolimod demonstrated similar efficacy in patients with RRMS regardless of prior treatment history (<a href="./references#CD009371-bbs2-0076" title="KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders. 2014; Vol. 3:341–9. ">Kremenchutzky 2014</a>). </p> </li> <li> <p>People with systemic disorders were excluded in all included trials, while in the real world comorbidity is frequent. Precautions and new recommendations need to be followed before and after starting treatment, or when restarting treatment with fingolimod (<a href="./references#CD009371-bbs2-0058" title="European Medicines Agency. Committee for medicinal products for human use (CHMP). Gylenia summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/002202/WC500104529.pdf(accessed December 2015). ">EMA 2011</a>; <a href="./references#CD009371-bbs2-0057" title="European Medicines Agency. Gilenya : EPAR ‐ Summary for the public. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&amp;mid=WC0b01ac058004d5c1(accessed Decembre 2015). [ema.europa.eu/Find medicine/Humanmedicines/European Public Assessment Reports] ">EMA 2015</a>). </p> </li> <li> <p>We did not plan to explore safety outcomes beyond the duration of primary RCTs. The Food and Drug Administration (FDA) required planning of two studies (<a href="./references#CD009371-bbs2-0060" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails2010; Vol. (accessed December 2015). ">FDA 2010</a>): </p> <ol id="CD009371-list-0011"> <li> <p>A post‐marketing observational prospective, parallel cohort study in relapsing multiple sclerosis patients to assess the potentially serious risk of: eye toxicity, cardiac and vascular toxicity, pulmonary toxicity, seizures, serious and opportunistic infections, malignancies, liver toxicity and atypical multiple sclerosis relapse. Specific outcomes examined should include, but not be limited to, macular oedema, symptomatic bradycardia, second and third degree atrioventricular block, and lymphoma. Final Report Submission: 15 December, 2020. </p> </li> <li> <p>Develop and maintain a prospective, observational pregnancy exposure registry study conducted in the United States. Final Report Submission: 31 October, 2017. </p> </li> </ol> </li> </ol> </p> <p>At 31 October, 2011, 89 pregnancies were reported in completed or ongoing clinical studies, with 74 pregnancies in fingolimod treatment arms. Of 66 pregnancies with in utero exposure to fingolimod, there were 28 live births, nine spontaneous abortions, 24 elective abortions (one case each of tetralogy of Fallot, spontaneous intrauterine death, and failure of fetal development), two infants were born with malformations (one with congenital unilateral posteromedial bowing of the tibia and one with acrania). There were five cases (7.6%) of abnormal fetal development in the 66 pregnancies. Considering also the known risk of teratogenicity in animals, women of childbearing potential should use effective contraception during fingolimod therapy and for two months after treatment discontinuation (<a href="./references#CD009371-bbs2-0018" title="KarlssonG , FrancisG , KorenG , HeiningP , ZhangX , CohenJ , et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology2014;82:674–80. ">Karlsson 2014</a>). </p> </section> <section id="CD009371-sec-0076"> <h3 class="title" id="CD009371-sec-0076">Quality of the evidence</h3> <p>We downgraded the quality of the evidence for all included outcomes at 24 months due to significant differences in reasons of incomplete outcome data between fingolimod 0.5 mg and placebo groups. We further downgraded the quality of evidence for disability worsening, withdrawals due to adverse events, and MRI gadolinium‐enhancing lesions due to insufficient information size and wide confidence intervals. We further downgraded the quality of evidence for withdrawals due to inconsistency. Overall we gave a GRADE rating of moderate for relapses, low for disability progression, very low for withdrawals due to adverse events, and low for MRI gadolinium‐enhancing lesions . </p> <p>We downgraded the quality of the evidence for all included outcomes at 12 months due to insufficient information size between the fingolimod 0.5 mg and intramuscular interferon beta‐1a groups in <a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a>, resulting in moderate quality evidence. We further downgraded the quality of evidence for disability worsening because this study required only three months’ follow‐up to confirm sustained disability worsening. Although we had to accept the definition given in the original paper, we assessed this definition as unreliable in capturing unremitting disability worsening. </p> </section> <section id="CD009371-sec-0077"> <h3 class="title" id="CD009371-sec-0077">Potential biases in the review process</h3> <p>The search strategy for the trials, and contacts initiated with the main investigators, suggest the likelihood that we identified all relevant studies and obtained all relevant data. </p> </section> <section id="CD009371-sec-0078"> <h3 class="title" id="CD009371-sec-0078">Agreements and disagreements with other studies or reviews</h3> <p>Previous reviews on fingolimod as compared with placebo or other approved DMDs in RRMS have been published, but only descriptive data have been reported (<a href="./references#CD009371-bbs2-0037" title="AliR , NicholasRS , MuraroPA . Drugs in development for relapsing multiple sclerosis. Drugs2013;73(7):623‐50. ">Ali 2013</a>; <a href="./references#CD009371-bbs2-0054" title="DoggrellSA . Oral fingolimod for relapsing‐remitting multiple sclerosis. Expert Opinion on Pharmacotherapy2010;11(10):1777‐81. ">Doggrell 2010</a>; <a href="./references#CD009371-bbs2-0062" title="FoxRJ , RudickRA . Risk stratification and patient counselling for natalizumab in multiple sclerosis. Neurology2012;78:436‐7. ">Fox 2012</a>; <a href="./references#CD009371-bbs2-0064" title="GajofattoA , TurattiM , MonacoS , BenedettiMD . Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing‐remitting multiple sclerosis. Drug Healthcare and Patient Safety2015;7:157‐67. ">Gajofatto 2015</a>; <a href="./references#CD009371-bbs2-0066" title="GoldR . Oral therapies for multiple sclerosis: A review of agents in phase III development or recently approved. CNS Drugs2011;25(1):37‐52. ">Gold 2011</a>; <a href="./references#CD009371-bbs2-0093" title="OhJ , O'ConnorPW . Safety, tolerability and efficacy of oral therapies for relapsing‐remitting multiple sclerosis. CNS Drugs2013;27:591‐609. ">Oh J 2013</a>). </p> <p>Other reviews have used a structured methodology, including network meta‐analysis, but they have considered a low number of RCTs, with different and limited endpoints. A systematic non‐Cochrane review assessed the efficacy and safety of fingolimod at different doses (<a href="./references#CD009371-bbs2-0041" title="BaoC , ZhouJH . Efficacy and safety of FTY720 in the treatment of relapsing‐remitting multiple sclerosis: A systematic review. Chinese Journal of Evidence‐Based Medicine2012;12(4):445‐50. ">Bao 2012</a>); it was based on three RCTs published up to 2010. The results showed that fingolimod was safe and effective in treating RRMS, considering clinical and MRI (incidence rate of so‐called "intense lesion" on T2‐weighted) endpoints. </p> <p>One review evaluated the comparative effects of fingolimod versus other DMDs using network meta‐analysis. It included ten studies, two of them assessing the effects of fingolimod (<a href="./references#CD009371-bbs2-0052" title="DelSantoF , MarateaD , FaddaV , TrippoliS , MessoriA . Treatments for relapsing‐remitting multiple sclerosis: summarising current information by network meta‐analysis. European Journal of Clinical Pharmacology2011;68:441‐8. ">Del Santo 2011</a>). The endpoint was limited to the relapse‐free rate at 12 months. The results suggested that fingolimod was superior to interferon beta‐1a (direct comparison) and glatiramer (indirect comparison) in terms of prevention of relapse at 12 months follow‐up. </p> <p>The results of a Cochrane review evaluating the effect of immunomodulators and immunosuppressants in people with RRMS using network meta‐analysis, demonstrated that alemtuzumab, natalizumab, and fingolimod are the best choices against the recurrence of relapses, but the evidence was limited to the first 24 months of follow‐up (<a href="./references#CD009371-bbs2-0105" title="TramacereI , DelGiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011381.pub2] ">Tramacere 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009371-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009371-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p> Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009371-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009371-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="N, number of patients; n, number of events.Significant differences (based on Fisher exact test) are reported in red." data-id="CD009371-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>N, number of patients; n, number of events.</p> <p>Significant differences (based on Fisher exact test) are reported in red.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="N, number of patients; n, number of events.* One case of basal‐cell carcinoma was not reported as a serious adverse event by the site investigator (Calabresi 2014).Significant differences (based on Fisher exact test) are reported in red." data-id="CD009371-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>N, number of patients; n, number of events.</p> <p>* One case of basal‐cell carcinoma was not reported as a serious adverse event by the site investigator (<a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a>). </p> <p>Significant differences (based on Fisher exact test) are reported in red.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Participants free from relapse, Outcome 1 At 6 months." data-id="CD009371-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Participants free from relapse, Outcome 1 At 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Participants free from relapse, Outcome 2 At 12 months." data-id="CD009371-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Participants free from relapse, Outcome 2 At 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Participants free from relapse, Outcome 3 At 24 months." data-id="CD009371-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Participants free from relapse, Outcome 3 At 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Participants free from disability worsening, Outcome 1 At 12 months." data-id="CD009371-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Participants free from disability worsening, Outcome 1 At 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Participants free from disability worsening, Outcome 2 At 24 months." data-id="CD009371-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Participants free from disability worsening, Outcome 2 At 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of withdrawals due to adverse events, Outcome 1 Withdrawals due to adverse events over 6 months." data-id="CD009371-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Number of withdrawals due to adverse events, Outcome 1 Withdrawals due to adverse events over 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of withdrawals due to adverse events, Outcome 2 Withdrawals due to adverse events over 12 months." data-id="CD009371-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Number of withdrawals due to adverse events, Outcome 2 Withdrawals due to adverse events over 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of withdrawals due to adverse events, Outcome 3 Withdrawals due to adverse events over 24 months." data-id="CD009371-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Number of withdrawals due to adverse events, Outcome 3 Withdrawals due to adverse events over 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of withdrawals due to adverse events, Outcome 4 Withdrawals due to serious adverse events over 6 months." data-id="CD009371-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Number of withdrawals due to adverse events, Outcome 4 Withdrawals due to serious adverse events over 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of withdrawals due to adverse events, Outcome 5 Withdrawals due to serious adverse events over 12 months." data-id="CD009371-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Number of withdrawals due to adverse events, Outcome 5 Withdrawals due to serious adverse events over 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of withdrawals due to adverse events, Outcome 6 Withdrawals due to serious adverse events over 24 months." data-id="CD009371-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Number of withdrawals due to adverse events, Outcome 6 Withdrawals due to serious adverse events over 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Annualised relapse rate, Outcome 1 At 6 months." data-id="CD009371-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Annualised relapse rate, Outcome 1 At 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Annualised relapse rate, Outcome 2 At 12 months." data-id="CD009371-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Annualised relapse rate, Outcome 2 At 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Annualised relapse rate, Outcome 3 At 24 months." data-id="CD009371-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Annualised relapse rate, Outcome 3 At 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Participants free from gadolinium‐enhancing lesions, Outcome 1 At 6 months." data-id="CD009371-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Participants free from gadolinium‐enhancing lesions, Outcome 1 At 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Participants free from gadolinium‐enhancing lesions, Outcome 2 At 12 months." data-id="CD009371-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Participants free from gadolinium‐enhancing lesions, Outcome 2 At 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Participants free from gadolinium‐enhancing lesions, Outcome 3 At 24 months." data-id="CD009371-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Participants free from gadolinium‐enhancing lesions, Outcome 3 At 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mean change of MRI T2‐weighted lesion load, Outcome 1 At 12 months." data-id="CD009371-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Mean change of MRI T2‐weighted lesion load, Outcome 1 At 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mean change of MRI T2‐weighted lesion load, Outcome 2 At 24 months." data-id="CD009371-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Mean change of MRI T2‐weighted lesion load, Outcome 2 At 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Quality of life, Outcome 1 At 6 months." data-id="CD009371-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Quality of life, Outcome 1 At 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009371-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/urn:x-wiley:14651858:media:CD009371:CD009371-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_t/tCD009371-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Quality of life, Outcome 2 At 24 months." data-id="CD009371-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Quality of life, Outcome 2 At 24 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/media/CDSR/CD009371/image_n/nCD009371-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009371-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants or population:</b> people with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> outpatients in multiple sclerosis centres<br/> <b>Intervention:</b> fingolimod 0.5 mg versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes at 24 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (placebo)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fingolimod 0.5 mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 100</b> <br/> (63 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b> <br/> (1.28 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 100</b> <br/> (83 to 91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> <br/> (1.02 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> l<b>ow<sup>a,b</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 100</b> <br/> (8 to 21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.42</b> <br/> (0.89 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1556<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a,b,c</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Annualised relapse rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.50</b> <br/> (0.40 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from MRI gadolinium‐enhancing lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 100</b> <br/> (83 to 94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> <br/> (1.27 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1226<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> l<b>ow<sup>a,b</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*For dichotomous outcomes, the <b>corresponding risk with fingolimod 0.5 mg</b> (and its 95% CI) is based on the <b>assumed risk with the control group</b> (i.e. the mean proportion of events in the control group across the two studies) and the <b>relative effect</b> of fingolimod (and its 95% CI). For the annualised relapse rate, only the relative effect (i.e., the rate ratio) is given, because the assumed risk with the control group is not estimable.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Study limitations: significant differences in reasons for incomplete outcome data between treatment and control groups.<br/> <sup>b</sup> Imprecision: total number of events (i.e. the number of participants with disability worsening/gadolinium‐enhancing lesions) was less than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size criteria. Wide confidence intervals.<br/> <sup>c</sup> Inconsistency: unexplained heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fingolimod 0.5 mg versus placebo for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009371-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fingolimod 0.5 mg versus interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Fingolimod 0.5 mg versus intramuscular interferon beta‐1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Participants or population:</b> people with relapsing‐remitting multiple sclerosis<br/> <b>Settings:</b> outpatients in multiple sclerosis centres<br/> <b>Intervention:</b> fingolimod 0.5 mg versus intramuscular interferon beta‐1a </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes at 12 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (interferon beta‐1a)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fingolimod 0.5 mg </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 100</b> <br/> (76 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.18</b> <br/> (1.09 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 100</b> <br/> (91 to 98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> <br/> (0.99 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> l<b>ow<sup>a,b</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>4 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>6 per 100</b> <br/> (3 to 10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.51</b> <br/> (0.81 to 2.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>860<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Annualised relapse rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.48</b> <br/> (0.34 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants free from MRI gadolinium‐enhancing lesions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 100</b> <br/> (85 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (1.05 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>728<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*For dichotomous outcomes, the <b>corresponding risk with the intervention</b> (and its 95% CI) is based on the <b>assumed risk with the control</b> (i.e. the mean proportion of events in the control group across studies) and the <b>relative effect</b> of the intervention (and its 95% CI). For the annualised relapse rate, only the relative effect (i.e., the rate ratio) is given.<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Imprecision: total number of events (i.e. the number of participants with disability worsening/gadolinium‐enhancing lesions) was less than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size criteria. </p> <p><sup>b</sup> Indirectness: surrogate outcome (progression confirmed at three months of follow‐up). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fingolimod 0.5 mg versus interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009371-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome measures and time points</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Clinical outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MRI outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point assessment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.Annualised relapse rate </p> <p>2. Time to disability progression confirmed at 3 months</p> <p>3. Time to disability progression confirmed at 6 months</p> <p>4. Safety</p> <p>5. Time to first relapse</p> <p>6. Proportion of relapse‐free participants</p> <p>7. Change from baseline to the end of study on the MSFC score</p> <p>8. Quality of life using the Euro quality of life scale (EQ‐5D)</p> <p>9. Patient Reported Indices in Multiple Sclerosis</p> <p>10. Fatigue using the Modified Fatigue Impact Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.Percent brain‐volume change from baseline at 24 months</p> <p>2.Number and volume of gadolinium‐enhancing T1 lesions</p> <p>3. Number of new or newly enlarged T2 lesions</p> <p>4. Proportion of participants free of gadolinium‐enhancing T1 lesions</p> <p>5. Proportion of participants free of new or newly enlarged T2 lesions</p> <p>6. Proportion of participants free of new inflammatory activity (no gadolinium‐enhancing T1 lesions and no new or newly enlarged T2 lesions) </p> <p>7. Percentage change from baseline in volume of gadolinium‐enhanced T1 lesions</p> <p>8. Percentage change from baseline in volume of new or newly enlarged T2 lesions</p> <p>9. Brain volume</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Annualised relapse rate </p> <p>2. Progression of disability (confirmed at 3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of new or enlarged lesions on T2‐weighted scans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Treatment satisfaction </p> <p>2. Fatigue</p> <p>3. Depression</p> <p>4. Activities of daily living</p> <p>5. Health‐related Quality Of Life</p> <p>6, Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Number of participants remaining free of relapse</p> <p>2. Annualised relapse rate</p> <p>3, Time to the first relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.Number of gadolinium‐enhanced lesions per participant recorded on T1‐weighted MRI at monthly intervals for 6 months </p> <p>2.Total volume of gadolinium‐enhanced lesions per participants</p> <p>3. Proportion of participants with gadolinium‐enhanced lesions</p> <p>4. Total number of new lesion per participant on T‐weighted images</p> <p>5. Changes in lesion volume on T2‐weighted images</p> <p>6. Brain volume from baseline to month 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Annualised relapse rate </p> <p>2. Time to confirmed disability progression (confirmed after 3 months )</p> <p>3. Time to a first relapse</p> <p>4. Time to disability progression (confirmed after 6 months)</p> <p>5. Changes in the EDSS score</p> <p>6. Changes in the MSFC z score between baseline and 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Number of gadolinium‐enhancing lesions</p> <p>2. Proportion of participants free from gadolinium‐enhancing lesions</p> <p>3. Number of new or enlarged lesions on T2‐weighted MRI scans</p> <p>4. Proportion of participants free from new or enlarged lesions on T2‐weighted scan</p> <p>5. Volumes of hyperintense lesions on T2‐weighted scan</p> <p>6. Volumes of hypointense lesions on T1‐weighted scans</p> <p>7. Change in brain volume between baseline and 24 months</p> <p>8. Safety and tolerability measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of participants free from relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants free from gadolinium‐enhancing lesions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>EDSS</b> : Expanded Disability Status Scale; <b>MSFC</b>: Multiple Sclerosis Functional Composite </p> <p>The primary outcome of each study is underlined</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome measures and time points</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009371-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of the population included in the RCTs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Drugs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Female (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Course of disease of RR‐SP (%) </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age, years, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean EDSS score (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Disease duration, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pre‐1 year number of relapses, mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Percentage of pre‐study treatment‐naive participants </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Percentage of participants with MRI enhancing lesions </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean lesion volume on T2‐weighted images (mm3 ) (SD)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40·1 (8·4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2·2 (1·5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10·6 (7·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1·5 (0·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5553 (7841)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40·6 (8·4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2·2 (1·4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10·4 (8·0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1·4 (0·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5484 (8000)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40·9 (8·9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2·3 (2·0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10·8 (8·2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1·5 (1·0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4936 (7286)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1a (Avonex)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.0 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.19 (1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4924 (5711)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.7 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.24 (1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 (6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5170 (6642)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.8 (8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.21 (1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3 (6.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5085 (5962)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DMD<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.1 (9.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 (1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7 (8.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.0 (9.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 (1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1 (8.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 ‐ 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.1 (19‐56)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (0.0‐6.5)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (0.2‐28.2)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 (0‐5)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8805 (123‐62,218)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 ‐ 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.0 (19‐60)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7 (0.0‐6.0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 (0.3‐50.2)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0‐5)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,219 (293‐104,504)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 5.0 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 ‐ 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.3 (18‐59)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (0.0‐6.0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 (0.5‐42.2)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0‐4)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8722 (349‐70,218)*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.2 (8.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (0.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6162 (7085)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.6 (8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 (6.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6128 (7623)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.4 (8.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6829 (8491)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 ‐ 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0 (8.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (7.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6 (22.6)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 0.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.7 ‐ 5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.0 (9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (6.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.4 (22.7)**</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fingolimod 1.25 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.2 ‐ 1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.0 (9.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.7 (23.3)**</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p><b>DMD:</b> disease‐modifying drug;<b>EDSS</b> : Expanded Disability Status Scale; <b>MRI</b> : magnetic resonance imaging; <b>NR</b> : not reported; <b>RR:</b> relapsing‐remitting; <b>SD</b> : standard deviation; <b>SP:</b> secondary progressive </p> <p>* Range (SD was not provided)<br/> ** Number of T2 lesions (volume was not provided)<br/> <sup>§</sup> interferon beta‐1b (Extavia® or Betaseron®) 0.25 mg injected subcutaneously every other day (46 participants); interferon beta‐1a (Avonex®) 30 μg intramuscular injected once a week (60 participants); interferon beta‐1a (Rebif®) 22 μg or 44 μg injected subcutaneously three times a week (65 participants); or glatiramer acetate (Copaxone®) 20 mg injected subcutaneously once‐daily (92 participants) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of the population included in the RCTs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009371-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Methods of adverse events monitoring</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the researchers actively monitor for adverse events (AEs) (low risk of bias) or did they simply provide spontaneous reporting of AEs that arose (high risk of bias)?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Did the authors define serious AEs (SAEs) according to an accepted international classification and report the number of SAEs?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0001" title="CalabresiP , RadueEW , GoodinD , JefferyD , KottilR , RederA , et al. Efficacy and safety of fingolimod in patients with relapsing‐remitting multiple sclerosis (RRMS): results from an additional 24‐month double‐blind, placebo‐controlled study (freedoms II study). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012. CalabresiPA , GoodinD , JefferyD , KapposL , LublinFD , RammohanK , et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing‐remitting multiple sclerosis. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis. 2012; Vol. 18. CalabresiPA , RadueEW , GoodinD , JefferyD , RammohanKW , RederAT , et al. Safety and efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis (FREEDOMS II): a double‐blind, randomised, placebo‐controlled, phase 3 trial. The Lancet Neurology2014;13:545–56. CoyleP , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. Fingolimod efficacy and safety in an African‐American patient subgroup from freedoms II. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, AAN 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. GoodinD , JefferyD , KapposL , LublinF , RadueEW , RammohanK , et al. Fingolimod reduces annualized relapse rate in patients with relapsing‐remitting multiple sclerosis: Freedoms II study subgroup analysis. Abstract meeting of the 65th American Academy of Neurology Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. KhanO , CreeB , CabreP , IngleseM , PerumalJ , MengX , et al. The efficacy and safety of fingolimod in an African‐American patient subgroup from FREEDOMS II. Abtract meeting of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 October 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. RadueE , GoodinD , JefferyD , KapposL , LublinF , RammohanK , et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing‐remitting multiple sclerosis: results from the phase 3. Multiple Sclerosis2012;18(4):322‐3. RederA , JefferyD , GoodinD , KapposL , LublinF , RadueE , et al. Long‐term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Multiple Sclerosis2013;19:510‐1. VollmerT , GoodinD , JefferyD , KapposL , RadueE , RammohanK , et al. Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing‐remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Multiple Sclerosis2012;18:438‐9. VollmerT , JefferyD , GoodinD , KapposL , LublinF , RadueEW , et al. Long‐term safety of fingolimod in patients with relapsing‐remitting multiple sclerosis: results from phase 3 freedoms II extension study. Neurology. 2013; Vol. 80. WingesKM , WernerJS , HarveyDJ , CelloKE , DurbinMK , BalcerLJ , et al. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing–remitting multiple sclerosis. Journal of Neuro‐Ophthalmology2013;33:322–9. ">Calabresi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>"We did extensive safety and tolerability assessments, in part as a response to preclinical safety concerns raised by the FDA and additional safety areas of interest identified in previous phase 2 and earlier clinical studies. We also recorded adverse events, serious adverse events, serious adverse events of special interest, 24 h Holter electrocardiography (ECG) post first‐dose and at 3 months, first‐dose bradycardia events, infections, laboratory tests, vital signs, ECG, echocardiography, pulmonary function.</i> tests, chest high‐resolution CT,<i>chest radiographs, ophthalmic examinations, including serial optical coherence tomography, and dermatological assessments." Clinical assessments were performed at screening and at randomisation (baseline), and study visits, including safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomisation</i>" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>"We also recorded adverse events, serious adverse events, serious adverse events of special interest, 24 h Holter electrocardiography (ECG) post fist‐dose and at 3 months, first‐dose bradycardia events, infections, laboratory tests, vital signs, ECG, echocardiography, pulmonary function</i> tests, chest high‐resolution CT,<i>chest radiographs, ophthalmic examinations, including serial optical coherence tomography, and dermatological assessments"</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0002" title="BarkhofF , CohenJ , MontalbanX , ComiG , AubersonL , HoldbrookF , et al. Fingolimod (FTY720) reduces brain volume loss over 12 months compared with intramuscular interferon beta‐1a: subgroup analyses of TRANSFORMS data based on inflammatory disease activity. Abstract meeting of the 5th Joint Triennal Congress of the European and Americas Committees for the treatment and research in Multiple Sclerosis; 2011 Oct 19–22, Amsterdam, The Netherlands. Multiple Sclerosis. 2011; Vol. 17. BarkhofF , deJongR , SfikasN , deVeraA , FrancisG , CohenJ , TRANSFORMS study group. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing‐Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis2014;20(13):1704‐13. CohenJA , BarkhofF , ComiG , HartungHP , KhatriBO , MontalbanX , et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):402‐15. CohenJA , BarkhofF , ComiG , IzquierdoG , KhatriB , MontalbanX , et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology2013;260(8):2023‐32. HartungH , BarkhofF , ComiG , KapposL , KhatriB , MontalbanX , et al. Relationship between early disease activity and long‐term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third meeting of the ENS; 2013 June 8‐11; Barcelona, Spain. Journal of Neurology. 2013; Vol. 260. KhatriB , BarkhofF , ComiG , HartungH , KapposL , MontalbanX , et al. Long‐term efficacy data from the extension of the phase III TRANSFORMS study of fingolimod versus Interferon beta‐1a in relapsing‐remitting multiple sclerosis: 4.5 year follow‐up. Journal of Neurology2012;259(1):S21. KhatriB , BarkhofF , ComiG , HartungHP , KapposL , MontalbanX , et al. Comparison of fingolimod with Interferon beta‐1a in relapsing‐remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology2011;10(6):520‐9. KhatriB , BarkhofF , ComiG , JinJ , FrancisG , CohenJ . Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN‐B1A: results from a phase 3, active‐controlled study (TRANSFORMS). Abstract meeting of the 64th American Academy of Neurology Annual Meeting, 2012, New Orleans, United States. Neurology. 2012; Vol. 78:1. MengX , CutterG , ChinP , HashmonayR , IslamMZ . Effect of switching from intramuscular Interferon B‐1a to fingolimod on time to relapse in patients with relapsing‐remitting multiple sclerosis enrolled in a 1‐year extension of transforms. Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2013, Lyon, France. Neurology. 2013; Vol. 80. MontalbanX , BarkhofF , ComiG , HartungHP , KapposL , KhatriB , et al. Long term efficacy of fingolimod in patients with relapsing‐remitting multiple sclerosis previously treated with interferon beta‐1a or disease modifying therapies: A post hoc analysis of the TRANSFORMS 4.5 year extension study. Journal of Neurology2013;260:S124‐5. ">Cohen 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"<i>An independent data and safety monitoring board evaluated overall safety in the fingolimod phase 3 program</i> " and <i>"Safety assessments were conducted during screening, at baseline, and at months 1, 2, 3, 6, 9, and 12</i>" (pg 404) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs were predefined per standard criteria (death, life‐threatening event, persistent disability, congenital defect, unplanned hospitalisation, or otherwise medically significant) (<a href="./references#CD009371-bbs2-0060" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails2010; Vol. (accessed December 2015). ">FDA 2010</a> Clinical review of safety pg 151) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0003" title="BarbatoL , SchofieldL , McCagueK , PestreichL , TobiasK , MalhotraM . Randomized, open‐label study to evaluate patient‐reported outcomes (PRO) with fingolimod after changing from prior disease‐modifying therapy (DMT) for relapsing multiple sclerosis (MS): EPOC study rationale and design. Abstract meeting of the 136th Annual Meeting of the American Neurological Association; 2011 Sept 25‐27; San Diego, United States. Annals of Neurology. 2011. CalkwoodJ , CreeB , CraytonH , KantorD , Brian SteingoB , BarbatoL , et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient‐ and physician‐reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurology2014;14(220):1‐11. CascioneM , WynnD , AgashivalaN , McCagueK , PestreichL , SchofieldL , et al. Summary scores for patient‐reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC). Multiple Sclerosis2012;18:488‐9. CascioneM , WynnD , BarbatoLM , PestreichL , SchofieldL , McCagueK . Randomized, open‐label study to evaluate patient‐reported outcomes with fingolimod after changing from prior disease‐modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics2013;16(7):859–65. CraytonH , HunterS , HuffmanC , AgashivalaN , SchofieldL , McCagueK , et al. Improved quality of life after therapy change to fingolimod. Journal of Neurology2013;260:S127. CreeB , KantorD , SteingoM , AgashivalaN , LiS , McCagueK , et al. Patient and physician reported outcomes after therapy switch from glatiramer acetate to fingolimod versus staying on glatiramer acetate. Multiple Sclerosis2013;19:464‐5. DiBernardoA , AgashivalaN , MengX , HashmonayR , BarbatoM , ChinP . Effect of fingolimod on two sub domains of the Beck depression inventory‐II In patients with relapsing multiple sclerosis. Abstract meeting of the 18th Annual Conference of Rehabilitation in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013. EdwardsK , CraytonH , CalkwoodJ , AgashivalaN , LiS , ChinP , et al. Patient‐and physician‐reported outcomes after therapy switch from interferon (beta) to fingolimod versus staying on interferon (beta) therapy. Abstract meeting of the 29th Congress of European Committee for Treatment and Research in MS; 2013 Oct 2‐5; Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19:231‐2. FoxE , EdwardsK , BurchJG , WynnDR , LaGankeC , CraytonH , et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2014;3(5):607–19. GudesblattM , AgashivalaN , RandhawS , LiS , BarbatoL , SingerB . Outcomes of a switch to fingolimod to treat relapsing multiple sclerosis: A patient subgroup post hoc analysis. Journal of Multiple Sclerosis2014; Vol. 2, issue 1:Open Access. HughesB , CascioneM , FreedmanM , AgiusM , KantorD , GudesblattM , et al. First‐dose effects of fingolimod after switching from injectable therapies in the randomized, open‐label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis2014;3(5):620‐8. SingerB , GudesblattM , AgashivalaN , LiS , RandhawaS , McCagueK , et al. Patient‐reported outcomes after therapy switch to fingolimod: post‐hoc subgroup analysis of the EPOC study. Abstract meeting of the 66th American Academy of Neurology Annual Meeting, April 26–May 3, 2014, Philadelphia, United States. Neurology. 2014; Vol. 82. ">Fox 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>"Safety and tolerability (secondary study objectives) were assessed via reporting of</i> <br/> <i>adverse events (AEs) and through physical examinations (ophthalmologist</i> <br/> <i>examinations, and evaluations of vital signs, chest x‐rays, and electrocardiograms</i> <br/> <i>[ECGs]), laboratory evaluations (measurement of hematology parameters, chemistry, urinalysis, serology, and lymphocyte counts)"</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0004" title="AntelJ , MontalbanX , O'ConnorP , deVeraA , CremerM , SfikasN , et al. Long‐term (7‐year) data from a phase 2 extension study of fingolimod in relapsing multiple sclerosis. Abstract meeting of The American Academy of Neurology, 64th AAN Annual Meeting; April 21 ‐ 28, 2012; New Orleans, United States. Neurology. 2012; Vol. 78. CohenJA , KhatriB , BarkhofF , ComiG , HartungHP , MontalbanX , et al. Long‐term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry 2015 June 25 [Epub ahead of print]. ComiG , O'ConnorP , MontalbanX , AntelJ , RadueEW , KarlssonG , et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results. Multiple Sclerosis2009;16:197‐207. IzquierdoG , O'ConnorP , MontalbanX , vonRosenstielP , CremerM , deVeraA , et al. Five‐year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Multiple Sclerosis2014;20(7):877‐81. KapposL , AntelJ , ComiG , MontalbanX , O'ConnorP , PolmanCH , et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine2006;355(11):1124‐40. MontalbanX , ComiG , AntelJ , O'ConnorP , deVeraA , CremerM , et al. Long‐term (&gt;7‐year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis. Journal of Neurology2012;259(1):S69‐70. MontalbanX , ComiG , O'ConnorP , GoldS , deVeraA , EckertB , et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health‐related quality of life in a phase II study. Multiple Sclerosis2011;17(11):1341‐50. MontalbanX , O'ConnorP , AntelJ . Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four‐year results from a phase II extension. Neurology. 2009; Vol. 72:A313. MontalbanX , O'ConnorP , IzquierdoG , VonRosenstielP , CremerM , PrutL , et al. Long‐term fingolimod (FTY720) in relapsing MS: 5‐year results from an extension of a phase II, multicentre study show a sustained low level of disease activity. Multiple Sclerosis2011;17(10):S442‐3. O'ConnorP , ComiG , MontalbanX , AntelJ , RadueEW , deVeraA , et al. Oral fingolimod (FTY720) in multiple sclerosis: two‐year results of a phase II extension study. Neurology2009;72(1):73‐9. ">Kappos 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>An independent external data and safety monitoring board evaluated adverse events and other safety data" and "Adverse events were assessed and reported at each visit (scheduled and unscheduled) by the treating physicians. Laboratory evaluations were undertaken at a central laboratory". "Vital signs were obtained at each visit, and laboratory and hematologic measures were obtained at baseline, day 1, and months 1,3,6,9, and 12. Electrocardiograms were obtained at baseline, on days 1 and 7, and at months 1,3,6,12, and 24 hour Holter electrocardiographic monitoring was performed at selected sites at baseline, day 1, and month 3. Pulmonary function tests... were performed at screening and months 6 and 12</i>" (pg 1126) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0005" title="BergvallN , SfikasN , AlsopJ , ChinP , VonRosensteilP , KapposL . Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies. Multiple Sclerosis2012;18(4):473‐4. CamuW , ThouvenotE , MeinelM , SfikasN , ChinP , Piani‐MeierD , et al. Influence of baseline clinical and demographic characteristics on disease evolution in the phase 3 FREEDOMS study in patients with relapsing‐remitting multiple sclerosis. Abtract meetings of the ECTRIMS 18th Annual Conference on Rehabilitation, 2013, Copenhagen, Denmark. Multiple Sclerosis. 2013; Vol. 19. ChinP , VonRosenstielP , HaeringD , FrancisG , KapposL . Fingolimod leads to early clinical and MRI benefits in relapsing‐remitting multiple sclerosis. Abstract meeting of the twenty‐third ENS, 2013, Spain. Journal of Neurology. 2013. CutterG , ChinP , FrancisG , MengX , HashmonayR , LublinF . Relapse is associated with residual deficits in relapsing‐remitting multiple sclerosis: Analysis of freedoms data. Abstract meeting, The American Academy of Neurology's 65th AAN Annual Meeting, 2013, San Diego, United States. Neurology. 2013; Vol. 80. DevonshireV , HavrdovaE , RadueEW , O'ConnorP , Zhang‐AubersonL , AgoropoulouC , et al. Relapse and disability outcomes in patients with multiple sclerosis treated with Fingolimod: subgroup analyses of the double‐blind, randomised, placebo‐controlled FREEDOMS study. The Lancet Neurology2012;11:420–8. HohlfeldR , CalabresiPA , O'ConnorP . Oral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease‐modifying therapies for multiple sclerosis and in patients who are treatment naive: subgroup analysis of data from a 24‐month phase III study (FREEDOMS). Journal of Neurology. 2010; Vol. 257. KapposL , DeSN , FreedmanMS , CreeBA , RadueEW , SprengerT , et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA‐4) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis 2015 Nov 19 [Epub ahead of print]. KapposL , O'ConnorP , RadueE , PolmanC , HohlfeldR , SelmajK , et al. Long‐term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015;84(15):1582‐91. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine2010;362(5):387‐401. KapposL , RadueEW , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Long‐term efficacy and safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis (RRMS): Results from the extension of the phase III FREEDOMS study. Neurology. 2012; Vol. 78:1. KremenchutzkyM , O'ConnorP , HohlfeldR , Zhang‐AubersonL , VonRosenstielP , MengX , et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Multiple Sclerosis and Related Disorders2013;3:341–9. O'ConnorP , PolmanC , HohlfeldR , SelmajK , OlssonT , AgoropoulouC , et al. Phase III FREEDOMS study extension: Long‐term safety of fingolimod (FTY720) in relapsing‐remitting multiple sclerosis. Multiple Sclerosis2012;18(4):223. RadueE , KapposL , O'ConnorP , PolmanC , HohlfeldR , CalabresiP , et al. Fingolimod significantly reduced brain volume loss in patients with relapsing‐remitting multiple sclerosis: 4‐year data from FREEDOMS extension study. Journal of Neurology. 2012; Vol. 259, issue 1:S21‐2. RadueE , SprengerT , deVeraA , FrancisG , RochotteE , TomicD , et al. Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study. Multiple Sclerosis2014;20:112‐3. RadueEW , O'ConnorP , PolmanCH , HohlfeldR , CalabresiP , SelmajK , et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology2012;69(10):1259‐69. ">Kappos 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>An independent data and safety monitoring board evaluated the safety</i> " and "S<i>tudy visits, including safety assessments, were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months after randomization</i>" (pg 389) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs were predefined per standard criteria (death, life‐threatening event, persistent disability, congenital defect, unplanned hospitalisation, or otherwise medically significant) (<a href="./references#CD009371-bbs2-0060" title="US Food and Drug Administration. Gilenya (Fingolimod) Product Approval Information 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=022527&amp;DrugName=GILENYA&amp;ActiveIngred=FINGOLIMOD&amp;SponsorApplicant=NOVARTIS&amp;ProductMktStatus=1&amp;goto=Search.DrugDetails2010; Vol. (accessed December 2015). ">FDA 2010</a> Clinical review of safety pg 151) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009371-bbs2-0006" title="KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology2014;14:1‐23. KiraJ , ItoyamaY , KikuchiS , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 12‐month, phase 2 extension study. Multiple Sclerosis2011;17(10):S193. SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis2012;18:1269–77. [PUBMED: 22354739] SaidaT , KikuchiS , ItoyamaY , HaoQ , KurosawaT , NagatoK , et al. Oral fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: Results of a 6‐month, randomised, double‐blind, placebo‐controlled, phase 2 study. Multiple Sclerosis2011;17:S418‐9. ">Saida 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"<i>Adverse events, serious adverse events assessments were conducted at screening, baseline, days 1 and 15, and months 1,2,3,4,5 and 6" (pg 2) and "Safety assessment included recording of AEs, SAEs, hematology values, vital signs, results of dermatological and ophthalmological examinations and results of pulmonary and liver function tests</i>" (Supplementary data online appendix) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorisation of SAEs conformed to ICH guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>AE: adverse event; CT: chest tomography; ECG: electrocardiography; FDA: Food and Drug Administration; SAE: serious adverse event </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Methods of adverse events monitoring</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/full#CD009371-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Participants free from relapse</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.96, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.11, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fingolimod 5.0 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.10, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.09, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fingolimod 1.25 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.06, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 At 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.28, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.29, 1.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Participants free from relapse</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Participants free from disability worsening</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.99, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 1.25 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.98, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [1.02, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [1.03, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Participants free from disability worsening</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Number of withdrawals due to adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawals due to adverse events over 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.53, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 0.5 mg versus DMDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.16, 8.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.63, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Fingolimod 5.0 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.62, 6.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to adverse events over 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.81, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fingolimod 1.25 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.54, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events over 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.89, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.48, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to serious adverse events over 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.42, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Fingolimod 0.5 mg versus DMDs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.83, 8.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.99, 5.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Fingolimod 5.0 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.04, 7.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to serious adverse events over 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.72, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Fingolimod 1.25 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.15, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to serious adverse events over 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.55, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Number of withdrawals due to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Annualised relapse rate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.28, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fingolimod 5.0 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.46, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.34, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fingolimod 1.25 versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.47, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 At 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.40, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.38, 0.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Annualised relapse rate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Participants free from gadolinium‐enhancing lesions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.33, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.34, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fingolimod 5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.35, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.30, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.30, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.05, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Fingolimod 1.25 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.06, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 At 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.27, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.33, 1.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Participants free from gadolinium‐enhancing lesions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Mean change of MRI T2‐weighted lesion load</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.30 [‐24.34, ‐6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.0 [‐25.23, ‐6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fingolimod 0.5 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐6.32, 5.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Fingolimod 1.25 mg versus interferon beta‐1a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.7 [‐9.18, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.43 [‐34.03, ‐6.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fingolimod 1.25 mg versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.51 [‐40.39, ‐24.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Mean change of MRI T2‐weighted lesion load</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009371-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Quality of life</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fingolimod 1.25 mg versus placebo (Hamburg Quality of Life Questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐9.13, 8.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fingolimod 0.5 mg versus DMDs (Change in FS36 Mental component summary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.8 [0.42, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fingolimod 0.5 mg versus DMDs (Change in FS36 Physical component summary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.30, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 At 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fingolimod 0.5 mg versus placebo (Euro quality of life scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.04, 0.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009371.pub2/references#CD009371-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009371.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009371-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009371-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009371-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009371-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009371-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD009371-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009371\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009371\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009371\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009371\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009371\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009371.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009371.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009371.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009371.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009371.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725329815"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009371.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725329819"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009371.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7893e87c936e',t:'MTc0MDcyNTMzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 